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“Nothing in this book is true.”
—Kurt Vonnegut, Cat’s Cradle

Abstract
Prostate cancer is the second most common cancer among men worldwide, yet its etiology remains
poorly understood. Obesity, on the other hand, is a prevalent but preventable medical condition that is
associated with hormonal and metabolic changes. Since prostate cancer is a hormone-related cancer, the
hypothesis of a link between body fatness and prostate cancer risk has been formulated. Furthermore,
the considerable biologic heterogeneity of prostate cancer warrants analyses to be carried out separately
by aggressiveness of the disease, differentiating indolent from potentially lethal tumors.
This thesis has two aims. First, to elucidate the association between obesity, as measured by body
mass index (BMI), and the risk of localized, advanced, and fatal prostate cancer. This is done using
both primary data (Paper I) and aggregated data extracted from published epidemiological studies
(Paper IV). Second, to deal with some methodological aspects related to the analysis of primary and
aggregated data (Paper II; Paper III; Paper V).
In Paper I, we used primary data from the Cohort of Swedish Men to examine the association of
BMI during early adulthood (30 years of age) and middle-late adulthood (45–79 years of age) with the
incidence of localized and advanced prostate cancer and with prostate cancer mortality. BMI during
middle-late adulthood was observed to be inversely associated with the incidence of localized prostate
cancer, while it was directly associated with the incidence of advanced prostate cancer and with prostate
cancer mortality. At the same time, we observed limited evidence of an inverse association between
BMI during early-adulthood and the risk of advanced and fatal prostate cancer.
In Paper II, we extended the use of quantile regression for censored data to those situations where
the time scale of interest is attained age at the event instead of follow-up time. In particular, we
described how to use Laplace regression to model percentiles of age at the event in the presence of
delayed entries, by conditioning on age at entry.
In Paper III, we identified three major misinterpretations of risk and rate advancement periods
(RAP): first, equating RAP with the difference in mean survival times; second, interpreting RAP as
the time by which the survival curve for the exposed individuals is shifted compared with that for the
unexposed; third, equating the RAP to a simple ratio of two log–relative risks. Furthermore, we showed
how RAP estimation is sensitive to the specification of the age-disease association.
In Paper IV, we carried out a dose–response meta-analysis to summarize the available evidence on
the association between BMI during middle-late adulthood and the incidence of localized and advanced
prostate cancer. Based on aggregated data extracted from 13 prospective studies, we observed that BMI
was inversely associated with the incidence of localized prostate cancer, while it was directly associated
with the incidence of advanced prostate cancer.
In Paper V, we stressed the importance of assessing the goodness of fit of dose–response meta-
analysis models. We presented and discussed three tools (deviance, coefficient of determination, and
decorrelated-residuals–versus–exposure plot) that are useful to test, quantify, and visually display the
fit of dose–response meta-analysis models, while taking into account the correlation structure of the
study-specific log–relative risks.
In conclusion, Paper I and Paper IV supported the hypothesis of etiological heterogeneity of prostate
cancer in relation to obesity during middle-late adulthood. In particular, BMI was observed to be directly
associated with advanced prostate cancer and with prostate cancer mortality. Paper II extended the
use of quantile regression for censored data to those situations where attained age is the time scale of
interest, Paper III clarified the appropriate use and interpretation of RAP, and Paper V proposed useful
and relevant methods for assessing the goodness of fit of dose–response models in research synthesis.
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Chapter 1
Introduction
“Epidemiological studies provide the only definitive information on the degree of
cancer risk to man. Since malignant diseases are clearly of multifactorial origin,
their investigation in man has become increasingly complex, and epidemiological
and statistical studies on cancer require a correspondingly complex and rigorous
methodology.”
—Lorenzo Tomatis1
Prostate cancer was the second most common cancer in men worldwide and the most
common one in developed countries in 2012 (Ferlay et al., 2015), yet its etiology remains
poorly understood. To date, the only established risk factors are those that are non-modifiable:
age, family history of the disease, and race/ethnicity (Grönberg, 2003).
The identification of potential modifiable risk factors is complicated by the considerable
biologic heterogeneity of the disease — ranging from indolent to potentially lethal tumors —
suggesting different etiologies and distinct entities (Discacciati and Wolk, 2014; Jahn et al.,
2015).
Obesity is a major global public health concern, with 205 million men worldwide estimated
to be obese. This obesity epidemic is particularly severe in developed countries, where, for
example, as much as 20% of men living in Western Europe and 30% in the U.S. were estimated
to be obese (Finucane et al., 2011).
Since body fatness is related to hormonal and metabolic changes and given that prostate
cancer is a hormone-related cancer, the hypothesis of an association between obesity and
prostate cancer risk — possibly depending on the aggressiveness of the disease — has been
repeatedly formulated (Hsing et al., 2007).
Elucidating the possible association between obesity and prostate cancer is not only impor-
tant to unravel the etiology of the disease, but it is also of public health significance, as these
two medical conditions affect large proportions of the male population. In addition, the fact
1Lorenzo Tomatis (*1929–†2007) was the Director from 1982 until 1993 of the International Agency for
Research on Cancer in Lyon, France. This quotation is taken from the foreword he wrote for the book “Statistical
methods in cancer research. Volume 2 — The analysis of cohort studies” (Breslow and Day, 1987).
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that obesity is a largely preventable condition might provide strategies for reducing prostate
cancer incidence and mortality.
As the words by Lorenzo Tomatis remind us, epidemiologic investigation cannot be sepa-
rated from epidemiologic methods. Likewise, the two aims of this thesis are intertwined.
First, this thesis focuses on elucidating the association of body fatness measured during
early and middle-late adulthood with localized and advanced prostate cancer incidence and
mortality. This is done by analyzing primary data from a large population-based cohort study
(Paper I) and by summarizing the existing epidemiologic evidence in form of aggregated data
(Paper IV).
Second, this thesis deals with some methodological aspects related to the analysis of pri-
mary and aggregated data. In particular, Paper II extends the use of quantile regression for
censored data to those situations where attained age is the time scale of interest, Paper III clari-
fies the appropriate use and interpretation of risk and rate advancement periods, while Paper V
presents relevant methods for assessing the goodness of fit of dose–response meta-analysis
models for binary outcomes.
Chapter 2
Background
2.1 Prostate cancer
Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive
system that is located just below the bladder, surrounding the urethra. More than 90% of all
prostate cancers develop from the gland cells and are referred to as adenocarcinomas.
Early prostate cancer is generally asymptomatic. However, symptoms include increased fre-
quency of urination, painful urination (dysuria), blood in the urine (hematuria), and erection
dysfunction. This group of symptoms is known as lower urinary tract symptoms. If the cancer
has metastasized to the bones, it can also cause bone pain, especially in the vertebrae, ribs, or
pelvis.
Prostate cancer is a very heterogeneous disease, ranging from indolent and slow-growing
tumors to aggressive and fast-developing tumors (figure 2.1). The majority of prostatic carcino-
mas are, however, slow-growing and the time period between onset and clinical presentation
of the disease can span several years. Men with this subtype of disease are likely to die from
unrelated causes, such as cardiovascular diseases. On the other extreme there are aggressive
cancers, which grow fast and may metastasize to the bone or lymph nodes, eventually causing
premature death. Figure 2.2 schematically exhibits the natural course of prostate cancer.
2.1.1 Descriptive epidemiology
Incidence
Prostate cancer was the second most common cancer in men worldwide and the most com-
mon one in more developed regions in 2012 (Ferlay et al., 2015). The age-standardized
Incidence Rates (IRs) showed large geographic variation, with the highest rates observed in
Australia/New Zealand (111.6 cases per 100,000 men), Northern America (97.2 cases per
100,000), and Western Europe (94.9 cases per 100,000 men). In contrast, the lowest IRs
were observed in Asia (9.4 cases per 100,000 men) (figure 2.3). Geographical differences
were present also within Europe, where, for example, the age-standardized IR in Sweden was
estimated to be around 1.7-times times of that in Italy (Ferlay et al., 2015).
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Figure 2.1: Heterogeneity of prostate cancer progression. The arrow labeled “fast” represents a fast-
growing cancer, one that quickly leads to symptoms and to death. The arrow labeled “slow” represents
a slow-growing cancer, one that leads to symptoms and death but only after many years. The arrow
labeled “very slow” represents a cancer that never causes problems because the patient will die of
some other cause before the cancer is large enough to produce symptoms. The arrow labeled “non-
progressive” represents cellular abnormalities that meet the pathological definition of cancer but never
grow to cause symptoms. Reproduced with permission from Welch and Black (2010).
Figure 2.2: Natural history of prostate cancer. This figure illustrates the course of prostate cancer
from initiation (A), to diagnosis by screening (B), to diagnosis by clinical symptoms (C), to clinically
detectable metastatic disease (D), and finally to death from prostate cancer (E). Reproduced with
permission from Salinas et al. (2014).
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Figure 2.3: Age-standardized prostate cancer incidence rates per 100,000 men, worldwide, 2012. Rates
are age-standardized to the World population. Source: GLOBOCAN 2012 (IARC).
In Sweden, the incidence of prostate cancer increased constantly during the period 1960–
2004, with a steeper increase starting from the mid-1990’s, and has been stable or even slightly
decreasing since then (1.5% average yearly decrease during 2004–2013) (figure 2.4). On
average, around 10,000 cases were diagnosed every year during the period 2009–2013 and
they amounted to 34% of the total cancer diagnoses (Engholm et al., 2015). Geographic
variation is present also within Sweden, where an almost 2-fold difference in prostate cancer
incidence was observed between counties according to NPCR data from 2000–2001 (Stattin
et al., 2005).
Mortality
Prostate cancer was the fifth leading cause of cancer death in men worldwide in 2012, with
an estimated total of 307,000 deaths (7% of the overall male cancer mortality) (Ferlay et al.,
2015). Geographical variation was less pronounced for mortality than for incidence (figure 2.5).
Unlike incidence, the highest age-standardized Mortality Rates (MRs) were observed in popu-
lations of African descent. However, the lowest MRs were, similarly to incidence, observed in
Asia (3.8 deaths per 100,000 men). Northern America showed slightly lower age-standardized
MRs as compared with Europe (9.8 versus 11.3 deaths per 100,000 men) (Ferlay et al., 2015).
In Sweden, MRs have been relatively stable over time (figure 2.4), with a 2.7% average
yearly decrease during the period 2004–2013. Still, around 2,400 men died on average every
year and accounted for 21% of all cancer deaths (2009–2013) (Engholm et al., 2015). The
5-year relative survival among men diagnosed with prostate cancer was around 90%, while
the 10-year survival was around 80% (as of 2012), showing a steady increase over time
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(Socialstyrelsen and Cancerfonden, 2013).
2.1.2 Classification
As a consequence of prostate cancer heterogeneity, its classification in risk categories at the
time of diagnosis has the important objective of grouping patients with a similar prognosis.
This allows primarily to make recommendations regarding their treatment, but also to compare
clinical, pathological, and epidemiologic data coming from different sources.
Different classification criteria have been developed with the aim of improving risk stratifi-
cation (Cooperberg et al., 2005; Boorjian et al., 2008; Heidenreich et al., 2014; Mohler et al.,
2014). These criteria are generally based on a combination of Tumor Node Metastasis (TNM)
staging system, Gleason grading system, and PSA serum level at diagnosis. In Sweden, the
criterion used by the NPCR is based on an adapted version of the National Comprehensive
Cancer Network classification scheme and has been slightly modified during the last years
(NPCR, 2013) (table 2.1).
In practice, epidemiologic studies employ different and sometimes inconsistent criteria to
classify prostate cancer. Moreover, the same terms are often used to refer to subtypes of cancer
defined in different ways, thus complicating the interpretation and comparison of the results.
For example, the term ‘advanced’ prostate cancer is variably defined as higher grade, later
stage, presence of metastatic disease or death, stage C or D on the Whitmore/Jewett scale, or
different combinations of these.
2.1.3 Prostate-specific antigen testing
PSA is an enzyme produced by the prostate’s epithelial cells and its primary function is to
liquefy the semen in the seminal coagulum. Low PSA levels are present in the blood of healthy
men and tend to increase naturally with age (Lilja et al., 2008). However, abnormally high
PSA levels may be a sign of prostate cancer or other prostatic diseases, such as benign prostatic
Table 2.1: Risk categories according to the NPCR classification criteria (NPCR, 2013).
Risk category Criterion
1. Low-risk T1–2, Gleason Score 2–6, PSA <10 ng⇥ml 1
1a. Very low-risk T1c, PSA <10 ng⇥ml 1, Gleason Score 2–6, no more than 2
biopsy cores with cancer, total length of biopsies <4mm
1b. Low-risk (other) Low-risk not categorized as 1a
1c. Low-risk (missing) Missing information for low-risk categorization according to
1a and 1b
2. Intermediate-risk T1–2, Gleason Score 7, and/or 10  PSA <20 ng⇥ml 1
3a. Localized high-risk T1–2, Gleason Score 8–10, and/or 20  PSA <50 ng⇥ml 1
3b. Locally advanced T3, PSA <50 ng⇥ml 1
4. Regionally metastatic T4 and/or N1 and/or 50  PSA <100 ng⇥ml 1, and Mx–0
5. Distant metastases M1 and/or PSA   100 ng⇥ml 1
6. Missing Missing information for categorization
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Figure 2.4: Age-standardized prostate cancer incidence and mortality rates per 100,000 men, Sweden,
1952–2013. Rates are age-standardized to the World population. The vertical axis is on the natural log
scale. Data source: NORDCAN.
Figure 2.5: Age-standardized prostate cancer mortality rates per 100,000 men, worldwide, 2012. Rates
are age-standardized to the World population. Source: GLOBOCAN 2012 (IARC).
8 2. Background
hyperplasia or prostatitis — that is, inflammation of the prostate. This reflects the fact that this
enzyme is organ-specific but not prostate cancer–specific.
In the U.S., PSA testing was introduced in the late 1980s and approved by the Food and
Drug Administration as a prostate cancer diagnostic marker in 1994 (Lilja et al., 2008). The ra-
tionale behind this test is to detect prostate cancer early on, giving the possibility of intervening
with curative treatments and, as a result, reduce the mortality from the disease. However, two
problems related to the PSA test are its low sensitivity and the risk of overdiagnosis — that is,
the diagnosis of a cancer “that would otherwise not go on to cause symptoms or death” (Welch
and Black, 2010). Using data from the placebo arm of the Prostate Cancer Prevention Trial
(PCPT), it was estimated that the test sensitivity is 24 and 35% for cut-offs of 3 and 4 ng⇥ml 1,
respectively (Thompson et al., 2006). More in general, PSA had a discrimination ability of
0.68, as measured by the area under the ROC curve (Thompson et al., 2006). Overdiagnosis,
which has been estimated to be in the range of 23–67% for prostate cancer (Draisma et al.,
2009; Welch and Black, 2010), can have a major impact on a man’s life both in terms of psycho-
logical burden due to the cancer diagnosis and in terms of side effects following unnecessary
treatment. Lastly, there is no conclusive evidence that PSA screening can in fact be useful to
reduce prostate cancer mortality (Cuzick et al., 2014), and the two largest randomized trials on
this matter — the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial, and
the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial — showed
conflicting results. Namely, the PLCO trial observed no evidence of a decrease in prostate
cancer mortality comparing systematic screening versus opportunistic screening, whereas the
ERSPC trial observed a 21% reduction in screened versus unscreened men. A recent study
using data from Swedish registers showed that more-intense PSA screening decreased prostate
cancer–specific mortality as compared with opportunistic screening, which might reconcile the
findings from the PLCO and ERSPC trials (Stattin et al., 2014). The value of using PSA as a
screening tool in the general population remains however controversial (Cuzick et al., 2014).
Sweden does not have, to date, a national screening program for prostate cancer. So-
cialstyrelsen [the National Board for Health and Welfare (NBHW)] carried out an extensive
literature review in 2013 and recommended against the introduction of a screening program
(Socialstyrelsen, 2013).2 Nevertheless, non-systematic, opportunistic PSA testing has increased
over time since its introduction in the 1990s, which can explain the increase in prostate cancer
incidence shown in figure 2.4 (Jonsson et al., 2011; Nordström et al., 2013; Socialstyrelsen,
2013). It has been estimated that around half of the Swedish men aged 55–69 years old are
PSA-tested, with large regional differences (Jonsson et al., 2011). In the Stockholm County,
the proportion of the 2011 male population that had been tested during the previous 9 years
was estimated to be between 46 and 77%, depending on the age group considered (Nordström
et al., 2013).
2“Hälso- och sjukvården bör inte erbjuda screening för prostatacancer med test av prostataspecifikt antigen
(PSA).”
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2.1.4 Risk factors
The etiology of prostate cancer is poorly understood, with the only established risk factors
being age, family history of the disease, and race/ethnicity. To date, prostate cancer is not
clearly linked to any preventable risk factors (Cogliano et al., 2011; Discacciati and Wolk,
2014; WCRF and AICR, 2014).
At the same time, WCRF and AICR recently updated the findings from the 2007 Second
Expert Report in their 2014 Continuous Update Project. The conclusions from the 2014 report
read “there is strong evidence that being overweight or obese increases the risk of advanced
prostate cancer (being overweight or obese is assessed by body mass index (BMI), waist cir-
cumference and waist-hip ratio)” (WCRF and AICR, 2014). The degree of evidence for body
fatness being associated with advanced prostate cancer, however, still does not reach the high-
est possible level of ‘strong evidence — convincing’.
Non-modifiable risk factors
Age is the strongest risk factor for prostate cancer. Diagnosis is very uncommon in men younger
than 40 years old and mortality is rare before the age of 50 years. It has been estimated that
only 25% of the incident cases in Europe in 2012 were diagnosed before the age of 65 years
(Ferlay et al., 2015). Similarly, in Sweden, only 30% of those men who received a prostate
cancer diagnosis in 2013 were younger than 65 years of age (Socialstyrelsen, 2014). Incidence
of prostate cancer increases sharply after the age of 55 years, peaks around 70–74 years of age,
and declines slightly thereafter (Ferlay et al., 2015). This steep trend in the age-incidence curve
has been observed in multiple populations, including populations where PSA screening was
completely absent (Armitage and Doll, 1954). Early-onset prostate cancer — that is, prostate
cancer diagnosed in men aged less than 55 years of age — has been suggested to be a distinct
phenotype, both from an etiological and clinical point of view (Salinas et al., 2014).
The risk of developing prostate cancer among men who have a first-degree relative with
prostate cancer is around 2.5 times the risk among men without a diagnosed first-degree
relative (Zeegers et al., 2003; Kicin´ski et al., 2011). This risk increases with decreasing age
of the proband, with increasing number of affected relatives, and if the affected relative is a
brother rather than the father. Family history is also associated to prostate cancer mortality
(Brandt et al., 2010). Familial aggregation of prostate cancer is largely due to genetic factors,
as suggested by twin studies, where heritability was estimated to be around 30–40% (Ahlbom
et al., 1997; Lichtenstein et al., 2000; Eeles et al., 2013). In the last 10 years, more than
70 low-penetrance susceptibility loci have been identified through genome-wide association
studies (Goh and Eeles, 2014). Familial aggregation can, however, be partly explained also by
increased screening propensity among men with family history of prostate cancer (Bratt et al.,
2010).
Racial/ethnic variation in prostate cancer risk is very pronounced, too. In the U.S., during
the period 2007–2011 (most recent available data), African-American men were observed to
have around 60% higher incidence and 140% higher mortality as compared with Caucasian
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men. Conversely, Hispanic men had approximately 10% lower incidence and mortality (ACS,
2015). These differences are partially due to a combination of genetic and lifestyle factors, but
disparities in socioeconomic status, as well as access to health care and prostate cancer screen-
ing may also contribute to explain the observed variation (Jones et al., 2008). Geographical
variation is also substantial (figure 2.3). Although this geographic variability can be explained
by differences in screening programs and in genetic factors, results from migrant studies sup-
port the hypothesis that lifestyle factors might play a role in prostate cancer etiology (Wilson
et al., 2012).
Body mass index
Since body adiposity is related to both hormonal and metabolic pathways and since prostate
cancer is a hormone-related cancer (Hsing et al., 2007), the investigation of a possible asso-
ciation between body fatness and prostate cancer risk has received considerable attention in
epidemiologic research. The picture regarding this potential association has become clearer
and more nuanced during the last 10 years or so.
BMI is probably the most common proxy for body adiposity in epidemiologic studies.3 In
fact, weight and height can be measured relatively simply and accurately even in large popu-
lations unlike waist circumference or waist-to-hip ratio. BMI may be inadequate to measure
body adiposity for a single individual, but it has been observed to correspond reasonably well
with percentage body fat within sex and age groups (Flegal et al., 2009).
By the late 2011,4 the existing body of literature on BMI and total prostate cancer was
quite extensive, but at the same time results were inconsistent. In particular, the largest meta-
analysis available to that date, which included 27 prospective studies for a total of more than
70 thousand prostate cancer cases, observed no evidence of an association between BMI and
total prostate cancer [Relative Risk (RR) for every 5-unit increment: 1.03 (95% Confidence
Interval (CI): 0.99–1.06)]5 and a high between-study heterogeneity (Renehan et al., 2008).
Similarly, the 2007 Second Expert Report published by WCRF and AICR observed no evidence
of an association, based on 24 prospective studies [RR for every 5-unit increment: 1.00 (95%
CI: 0.99–1.01)]. As a consequence, body fatness was listed among those factors for which no
conclusions could be reached (strength of the evidence: ‘limited — no conclusion’) (WCRF
and AICR, 2007, section 7.14).
The hypothesis that the association between body adiposity and prostate cancer risk could
differ according to the aggressiveness of the disease — therefore suggesting etiological hetero-
geneity of prostate cancer related to obesity — repeatedly appeared in the literature during
those years (Freedland et al., 2006a; Freedland and Platz, 2007; Hsing et al., 2007, 2008). The
available epidemiologic evidence supported this intriguing hypothesis, but at the same time it
3BMI is calculated as kg⇥m 2 — that is, weight in kilograms multiplied by height in meters to the power of
minus 2.
4The beginning of my graduate studies.
5The term ‘relative risk’ will be used in this thesis as a generic term for the risk ratio, hazard rate ratio, incidence
rate ratio, or odds ratio.
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was still limited. In fact, just a few studies had looked into the association between body adipos-
ity and prostate cancer by subtype of the disease. As a result, the only available meta-analysis
that carried out separate analyses by subtype of prostate cancer included 4 case-control and 6
prospective studies (two of which were very small), for a total of less than 2 thousand cases.
Despite this, a positive association between BMI and the risk of advanced prostate cancer was
observed [RR for every 5-unit increment: 1.12 (95% CI: 1.01–1.23)] (MacInnis and English,
2006).
During the years following the meta-analysis by MacInnis and English (2006) and the Sec-
ond Expert Report (WCRF and AICR, 2007), a considerable amount of epidemiologic research
on body adiposity and prostate cancer has been carried out, including Paper I of this thesis. Fur-
thermore, epidemiologic studies started to systematically report results separately by specific
subtypes of prostate cancer, although with the limitations described in section 2.1.2, allowing
a clearer picture to emerge. Paper IV was the first meta-analysis after the one published by
MacInnis and English (2006) to summarize the available evidence on BMI and prostate cancer
risk by subtype of the disease. In particular, Paper IV was considerably larger, including 13
prospective studies and about 6 times the number of prostate cancer cases. Results showed
an increased risk of advanced prostate cancer [RR for every 5-unit increment: 1.09 (95% CI:
1.02–1.16)] and a decreased risk of localized prostate cancer [RR for every 5-unit increment:
0.94 (95% CI: 0.91–0.97)]. Lastly, the 2014 Continuous Update Project report showed very
similar results to those of Paper IV for advanced prostate cancer [RR for every 5-unit increment:
1.08 (95% CI: 1.04–1.12)], while a non-linear association was observed for localized prostate
cancer (WCRF and AICR, 2014). An overview of the results from meta-analyses on BMI and
prostate cancer incidence — including the updated dose–response meta-analysis based on
Paper IV and described in section 5.4.2 — is reported in table 2.2.
In conclusion, the official recommendations issued in 2014 by the WCRF and ARIC read “to
reduce the risk of developing advanced prostate cancer, we recommend maintaining a healthy
weight” (WCRF and AICR, 2014).
Given that prostate cancer has usually a long latency period, spanning even decades be-
tween tumor initiation and diagnosis, body adiposity earlier in life could in theory play an
important role in tumor initiation and development. Moreover, the prostate may be more
susceptible to carcinogenic exposures during the developmental stages and immediately there-
after (Sutcliffe and Colditz, 2013). For these reasons, BMI during childhood, puberty, and early
adulthood — defined as ages between 18 and 30 years — has been investigated by epidemio-
logic studies, including Paper I of this thesis. The results, however, are inconsistent (Sutcliffe
and Colditz, 2013).
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2.2 Survival analysis of primary data
Survival analysis refers to the analysis of time from a specific time point until the occurrence
of a well-defined event (survival time).6 A unique characteristic of survival data is that ob-
servations may be censored — that is, for some study individuals the event time is unknown.
There are different censoring mechanisms, but right-censoring — arguably the most common
in epidemiologic studies — is the only type of censoring considered in this thesis. Furthermore,
we will make the assumption that survival time and censoring time are independent, possibly
conditional on a vector of known, fixed covariates.
With no censoring, survival time can be analyzed as any other numeric variable, for example
using Wilcoxon’s rank-sum test or standard quantile regression. When censoring is present,
a number of statistical tools is available to deal with this mechanism. However, one should
always remember that the ultimate goal is to describe the distribution of survival time, and
how this is affected by a vector of covariates.
Lastly, the term ‘primary data’ (or ‘individual patient data’) refers to the availability of raw
data for each participant in an epidemiologic study or clinical trial, as opposed to aggregated
data.
2.2.1 Basic statistical concepts
The statistical concepts introduced in this section are standard and therefore only a brief
overview will be given. See for example Kleinbaum and Klein (2012) for a more rigorous and
detailed exposition.
Let T be a continuous, non-negative random variable with probability density function
(p.d.f.) f (t), and cumulative density function (c.d.f.) F(t) = Pr(T  t), which gives the
probability that the event has occurred by time t. Usually, one observes the possibly right-
censored random variable Y = min(T,C), where C is the censoring random variable. In
addition to the p.d.f. and the c.d.f., there are three alternative but equivalent functions to
describe the distribution of T . These are the survival function, the hazard function, and the
cumulative hazard function.
The survival function S(t) gives the probability that the survival time is larger than t —
that is, the probability of being event-free at time t. It is a non-decreasing function of t and
can take values between 0 and 1. S(t) is equal to 1 minus the c.d.f.:
S(t) = Pr(T > t) = 1  F(t) =
Z +1
t
f (s)ds. (2.1)
A common non-parametric estimator for the survival function is the Kaplan-Meier product-
limit estimator (Kaplan and Meier, 1958).
A different characterization of the distribution of T is given by the hazard function h(t),
6The terms ‘event’, ‘outcome’, and ‘disease’ are equivalent and therefore they are used interchangeably in this
thesis.
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which is defined as:
h(t) = lim
d t!0
Pr(t < T  t + d t|T > t)
d t
. (2.2)
The numerator of the hazard function is the conditional probability that the event of
interest will happen in the time interval (t, t + d t), given that it has not occurred before. The
denominator is the width d t of such a time interval. By dividing the first by the second, one
obtains the event rate per unit of time, and taking the limit as d t goes to 0, the instantaneous
event rate. Therefore, h(t)d t, for an infinitesimal d t, is akin to the conditional probability that
the event will occur in the time interval (t, t+ d t) given S(t). However, the hazard itself is not
a probability (and in fact it is not bounded between 0 and 1). The key feature of the hazard
function is its conditional nature. Contrast, for example, the unconditional probability, for all
the men born on a given year, of dying after 40 years of age [S(40)], with the probability
of dying in the time interval (39 < T  40 years | alive at 39 years). For example, S(40) was
estimated to be around 60% for men born in 1861 in Sweden. However, given survival up to
39 years of age, the probability of being alive at age 40 years was much higher, roughly 98%
(SCB, 2010).
Lastly, the cumulative hazard function is the integrated hazard function:
H(t) =
Z t
0
h(s)ds.
All the functions described above are mathematically related and in particular,
S(t) = exp ( H(t)) = exp
Ç
 
Z t
0
h(s)ds
å
. (2.3)
2.2.2 The proportional-hazards approach to survival modeling
In the previous section we focused on how to characterize the distribution of T . However, a
major objective in epidemiologic research is to describe the variation in the distribution of T —
and therefore in survival — among individuals, given a vector of covariates. Different “classical”
approaches to survival modeling are available, the most common probably being Accelerated
Failure Time models and proportional-hazards (PH) models. An additional approach was re-
cently introduced by Royston and Parmar (2002).7 In this section we will give a brief overview
of the PH model. The literature on this topic is enormous and the reader can refer for example
to Therneau and Grambsch (2000), Kalbfleisch and Prentice (2002), and van Houwelingen
and Stijnen (2013) for a more complete discussion.
The proportional-hazards model
The PH model focuses directly on the hazard function. In particular, the hazard at time t,
for a given individual i with covariate vector xi = (xi1, . . . , xik) (not including a constant), is
7Royston-Parmar models include, but are not limited to, PH models.
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assumed to be:
hi(t|xi) = h0(t)exp
Ä
x>i  
ä
, (2.4)
where h0(t) is the baseline hazard for all individuals with xi = (0, . . . , 0),   =
 
 1, . . . , k
 
is
the vector of unknown model coefficients, and exp
Ä
x>i  
ä
is a proportional (multiplicative)
increase or reduction of the baseline hazard associated with the covariates xi — that is, the
Hazard Rate Ratio (HRR). Of note, this proportional increase or reduction in baseline hazard
is constant over t. In other words, PH models assume that the relative effect of a covariate is
the same at all time points.
An immediate consequence of models written in the form of equation (2.4), is that the
cumulative hazards are proportional too. In fact, integrating both sides of the equation from 0
to t gives the following result:
Hi
 
t|xi = Z t
0
h0(s)exp
Ä
x>i  
ä
ds = H0(t)exp
Ä
x>i  
ä
. (2.5)
Moreover, given equation (2.3), the following relation for the survival function is immediately
obtained:
Si(t|xi) = S0(t)exp(x>i  ). (2.6)
This important result says that, for PH models, the effect of the covariate vector xi on
the survival function is to raise S0(t) (the baseline survival function) to a power equal to
the constant exp
Ä
x>i  
ä
. As Kalbfleisch and Prentice (2002, pg. 118) pointed out “note that
the assumed model constraints the estimates so that one survivor function dominates the
other. Such graphs can give a misleading impression that one of the treatments is consistently
preferable and suggest significant differences even when they are not present.”
Time-dependent coe cients
The PH model lends itself to extensions, such as time-varying covariates and time-dependent
coefficients. In particular, time-dependent coefficients are useful to relax the assumption of
proportionality of the hazards over time. To accommodate time-dependent coefficients, the PH
model can be rewritten as:
hi(t|xi) = h0(t)exp
Ä
x>i  (t)
ä
, (2.7)
and the time-dependent coefficients are modeled using b transformations of time. For example,
suppose that only one coefficient  (t) is included in the model, then
 (t) =
bX
j=1
  j g j(t). (2.8)
This extended model — sometimes referred to as ‘extended PH model’ or ‘general hazard
rate model’ — implies that the HRR is free to vary over time (time-dependent HRR). Another
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consequence is that the simple equation (2.6) does not longer apply, as the coefficients are
now a function of time and therefore they cannot be taken out of the integral in equation (2.5).
The survival curve for the i-th individual is now given by:
Si(t|xi) = exp
Ç
 
Z t
0
h0(s)exp
Ä
x>i  (s)
ä
ds
å
. (2.9)
Calculation of the survival curve is still possible, but is now more complicated. The integral
in equation (2.9) can be derived analytically (in simple parametric situations) or numerically,
as a cumulative sum of predictions. The latter approach is described in detail by Carstensen
(2005, section 4). The complexity in the calculation of model-based survival curves is certainly
a drawback of PH models with time-dependent coefficients. At the same time, one should keep
in mind that these models put the focus on the HRR, which on the other hand is quite simple
to calculate even in the presence of time-dependent coefficients (Heinzl and Kaider, 1997).
The consequences on the HRR of the omission of time-dependent coefficients when actually
needed are numerous in the literature (see, for example, Royston and Parmar, 2011; Uno et al.,
2014). Figure 2.6, on the other hand, shows an example of such consequences on model-based
predicted survival curves. In particular, in panel A the hazards were forced to be proportional
[equation (2.6) for the survival curves applies], whereas in panel B this assumption was relaxed
by including a time-dependent coefficient [equation (2.9) for the survival curves applies].
Model fitting
There are different possible approaches to fitting hazard rate models.
The first is the ‘pure’ parametric approach, where the time variable T is assumed to follow
a specific distribution. Consequently, a specific functional form is assumed for the baseline
hazard h0(t). Examples of distributions used to characterize T are the exponential, Weibull,
and Gompertz distribution.
The second approach might be referred to as the ‘flexible’ parametric approach.8 With this
approach, time is split into non-overlapping intervals and the assumption that the baseline
hazard h0(t) is constant within each interval is made, leading to a so-called piece-wise expo-
nential model. If time is split finely enough, one can use a smooth, flexible function of time
to model h0(t). Time-dependent HRRs are easily accommodated by including interactions
(product terms) between covariates and transformations of time.9 Since an exponential distri-
bution for T is assumed within each time interval, these models are closely related to Poisson
regression (Breslow and Day, 1987, section 4.2).
The third approach is the ‘semi-parametric’ approach, where the association between the
covariates and the hazard is modeled parametrically — similarly to the other two approaches —
but the baseline hazard h0(t) is left unspecified. This approach is based on a partial likelihood
8Not to be confused with the flexible parametric survival model by Royston and Parmar (Royston and Parmar,
2002; Royston and Lambert, 2011), which is not covered in this thesis.
9This shows that, practically, models with time-dependent coefficients can be handled in the same way as models
with time-varying covariates (van Houwelingen and Stijnen, 2013).
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Figure 2.6: Consequences of the violation of the PH assumption on the predicted survival curves. In
panel A, a PH model without time-dependent coefficients was employed. The model-based predicted
survival curves for women in the active treatment (red solid line) and in the placebo arm (blue solid
line) were far off from the corresponding non-parametric Kaplan-Meier estimates (dashed lines). In
panel B, the time-dependent coefficient for the binary variable indicating the treatment group was
modeled using restricted cubic splines with 5 knots. As a result, the model-based predicted survival
curves followed closely the corresponding non-parametric estimates. Note how in panel B the model-
based survival curves cross after around 3.5 years, following the behavior of the Kaplan-Meier estimates.
See Hulley et al. (1998) for more information about the data.
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function introduced by Cox (1972). Non-parametric estimates, following a Cox model, of
the baseline survival function and of the cumulative hazard function can be calculated as
described by Kalbfleisch and Prentice (2002, section 4.3). A smooth estimate of the baseline
hazard can then be obtained by smoothing the cumulative hazard function using a kernel
estimator as described for example in Breslow and Day (1987, section 5.3) and Cleves et al.
(2010, section 8.4), or by simple parametric modeling of the estimated cumulative hazard
function (Royston, 2011).
The boundaries between the approaches described above are not clear-cut. In fact, the
‘flexible’ parametric approach is ultimately a ‘pure’ parametric approach. Likewise, conditional
Poisson regression is equivalent to Cox regression — that is, the contribution of each subject
to the the profile log-likelihood for   of a Poisson model, where time is split at each failure
time, is the same as the contribution of the j-th event time to the partial log-likelihood of a
Cox model. This extends to the more general case where tied events are present (Carstensen,
2005; Royston and Lambert, 2011).
2.2.3 The percentile approach to survival modeling
Due to the widespread use of PH models, the HRR — time-varying or otherwise — has become
the standard summary for comparing the survival between different groups of individuals.
An alternative, complementary approach to compare such differences is to focus on survival
percentiles and, specifically, on percentile differences (PDs).
Survival percentiles
The 100p-th survival percentile of the previously defined random variable variable T is the
time t by which 100p% of the study population has experienced the event of interest (where
0 < p < 1 is the survival quantile). For example, 25th survival percentile is the time t by
which 25% of the study population has experienced the event. Likewise, one could say that a
randomly selected individual from this study population has 0.25 probability of experiencing
the event within time t (and consequently 0.75 probability of experiencing it after time t).
Therefore, survival percentiles provide the link between a given probability of experiencing
the outcome and the time by which that probability is reached.
More formally, the 100p-th survival percentile is defined as:
QT (p) = inf
 
t : Pr (T  t)  p .
The function QT (·) is the quantile function, and is defined as that function such that 1  
S
 
QT (p)
 
= F
 
QT (p)
 
= p, where F(·) is the c.d.f. of T introduced at the beginning of
section 2.2.1. Of note, not all the survival percentiles are always estimable. It is not possible
for example to calculate the 25th survival percentile for the survival curves presented in figure
2.7. This is because at the end of the follow-up time, only around 15% of the individuals had
experienced the event of interest (coronary heart disease). However, all the percentiles up to
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Figure 2.7: Non-parametric survival curve estimate for all the women enrolled in the HERS trial (solid
line) (Hulley et al., 1998). The dashed line illustrates the 5th survival percentile (around 1.4 years).
the 15th are estimable. For example, the 5th survival percentile obtained from the Kaplan-
Meier estimate of the survival curve was around 1.4 years (dashed line).
One might want to estimate the 100p-th survival percentile conditional on a given covariate
vector x. In this case, the definition of survival percentiles easily extends to:
QT (p|x) = inf t : Pr (T  t|x)  p ,
and comparisons between groups of individuals (for example, exposed and unexposed) in
terms of time elapsed before a certain proportion of individuals has experienced the event
can be made. For example, in figure 2.6, the 5th survival percentile for those women in the
active treatment arm (red dashed line) was around 1.3 years, whereas the same percentile
was around 1.6 years for those women in the placebo arm (blue dashed line). As a result, the
5th PD between the placebo and treatment arm was 0.3 years. On the other hand, the 15th PD
was practically equal to 0 years.
A statistical method that combines the flexibility of a modeling approach with the simplicity
of focusing directly on survival percentiles is quantile regression for censored data.
Quantile regression for censored data
The idea behind quantile regression for censored data is to link the conditional 100p-th sur-
vival percentile QTi (p|xi) to the covariate vector xi =
 
xi1, . . . , xik
 
(generally including an
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intercept) though a linear, additive model. In particular:
QTi (p|xi) = x>i  (p) =
kX
j=0
  j(p)xi j . (2.10)
Some considerations regarding this model are necessary. First, the notation  (p) underlines
the important characteristic that the model coefficients are not constrained to be equal for
different survival percentiles. Therefore, no assumptions similar to the proportionality of the
hazards are made.
Second, the linear predictor x>i  (p) can include flexible transformations of continuous
covariates (such as splines of fractional polynomials), product terms, and the like. This model
is perfectly suited for the analysis of epidemiologic data, where it is important to be able to
model continuous covariates and adjust for confounding.
Third, by estimating multiple percentiles, one can thoroughly describe the distribution of
T , conditionally on x.
Fourth, the interpretation of the coefficients is particularly useful and straightforward, and
it is strictly related to how one would interpret the coefficients of a classical linear regression.
For example, just like in linear regression one would interpret a coefficient for a continuous
variable z as “the change in the mean response variable for every 1-unit increase in z, adjusting
for the other covariates in the model”, the interpretation of a similar coefficient from a quantile
regression for survival data is “the change in the 100p-th survival percentile for every 1-unit
increase in z, adjusting for the other covariates in the model”. The model coefficients are, in
other words, PDs (and therefore absolute measures of association).10
Lastly, and most importantly, the model coefficients are now expressed in the metric of time,
which means that they provide an intuitive measure of association between the covariates and
the event of interest. This in contrast with the HRR, which is a dimensionless measure of
association and possibly more difficult to interpret (Uno et al., 2014).
Different methods have been proposed to deal with the model-based estimation of condi-
tional percentiles when data is censored (Powell, 1986; Portnoy, 2003; Peng and Huang, 2008;
Wang and Wang, 2009; Bottai and Zhang, 2010). A description of the methods by Powell,
Portnoy, and Peng and Huang can be found in Koenker (2008). In this thesis and in Paper II,
however, we will deal with the approach developed by Bottai and Zhang (2010) and known
as ‘Laplace regression’.
Laplace regression
Re-introducing the notation used before, let Yi = min(Ti ,Ci) be the observed survival time
measured on the i-th out of n individuals. Moreover, let di be indicator variable which takes
value 1 if the survival time Yi is not censored and value 0 otherwise.
10With the usual exception regarding the coefficient for the intercept, for the product terms, and for splines or
other non-linear transformations of continuous variables.
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Assume that
Ti = x>i  (p) + ✏i , (2.11)
where xi is the covariate vector,  (p) is the vector of unknown model coefficients, and ✏i are
independently and identically distributed errors that follow a standard Laplace distribution,
which is equivalent to an asymmetric Laplace (AL) distribution with location parameter 0 and
scale parameter 1. For any given p, the p-th quantile of the conditional distribution of Ti given
xi is x>i  (p) — that is, QTi (p|xi) = Pr(Ti  x>i  (p)|xi) = p (Bottai and Zhang, 2010).
The AL distribution has a location parameter µ(p) and a scale parameter  (p). This no-
tation underlines the fact that, in the specific situation presented in this thesis, p is not a
parameter to be estimated, rather it is treated as fixed. The AL distribution has the following
p.d.f.:
fAL (s) =
p
 
1  p 
 (p)
exp
✓
  s µ(p)
 (p)
⇥
p  I  s  µ(p) ⇤◆ , (2.12)
where  (p)> 0,  1 < µ(p)< +1, and I(·) is the indicator function (Yu and Zhang, 2005).
Therefore, since the asymmetric Laplace in (2.12) is a location-scale family of densities, Ti
follows an AL distribution with p.d.f conditional to xi equal to:
fAL
 
ti |xi = p  1  p  (p) exp
Ç
  ti   x
>
i  (p)
 (p)
î
p  I Äti  x>i  (p)äóå , (2.13)
and c.d.f.
FAL
 
ti |xi =expÇ  ti   x>i  (p) (p) îp  I Äti  x>i  (p)äó
åî
p  I Äti > x>i  (p)äó
+ I
Ä
ti > x
>
i  (p)
ä (2.14)
as derived by Bottai and Zhang (2010). The subscript AL in fAL(·) and FAL(·) is used to dis-
tinguish these functions from the p.d.f. and c.d.f. of T , respectively. Heteroskedasticity of the
error term can be accommodated by allowing the scale parameter  (p) to depend on a vector
of covariates.
The contribution to the likelihood function L of an uncensored observation (di = 1) is
given by the p.d.f. in (2.13) evaluated at the observed survival time yi — that is Li = fAL(yi).
On the other hand — under the assumption of non-informative censoring conditionally on xi —
a censored observation (di = 0) carries only the information that his/her event time ti is larger
than yi . The contribution to the likelihood function is therefore Li = 1  FAL(yi). Consequently,
the likelihood function is proportional to:11
L( (p), (p); yi ,xi , di) =
nY
i=1
fAL(yi |xi)di  1  FAL(yi |xi) (1 di) .
11Note that this way of constructing the likelihood function also applies to parametric PH models under condi-
tional independent right-censoring. See for example Lawless (2003, chapter 5) or Kalbfleisch and Prentice (2002,
chapter 3).
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The log-likelihood function is obtained as usual by taking the logarithm of the likelihood:
l( (p), (p); yi ,xi , di) =
nX
i=1
⇥
di log fAL(yi |xi) +  1  di  log 1  FAL(yi |xi) ⇤ . (2.15)
Lastly, by substituting equations (2.13) and (2.14) in (2.15), and after some algebraic
manipulations, the log-likelihood function becomes:
l( (p), (p); yi ,xi , di) = di
ñ
  yi   x
>
i  (p)
 (p)
Ä
p  I Äyi  x>i  (p)ää+ log p  1  p  (p)
ô
+
 
1  di  I Äyi  x>i  (p)ä logñ1  p expÇ(1  p) yi   x>i  (p) (p)
åô
+
 
1  di Ä1  I Äyi  x>i  (p)ääñlog 1  p   p yi   x>i  (p) (p)
ô
.
(2.16)
The maximum likelihood (ML) estimators for the model parameters  ˆ(p) and  ˆ(p) are
defined as the maximizers of the log-likelihood (2.16), which can be directly maximized using,
for example, the gradient search algorithm recently proposed by Bottai, Orsini, and Geraci
(2015). Inference on the parameters can be obtained through bootstrapping, as initially pro-
posed in Bottai and Zhang (2010), or following standard asymptotic theory, as shown in Bottai
and Orsini (2013).
Note that when censoring occurs with zero probability before the survival percentile being
estimated, Laplace regression reduces to traditional quantile regression (Bottai and Zhang,
2010).
Thanks also to the development of a user-friendly command to estimate Laplace regression
with Stata (Bottai and Orsini, 2013), quantile regression for censored data has been repeatedly
employed in the recent years to analyze survival data in epidemiology (see, for example, Riz-
zuto et al., 2012; Bellavia et al., 2014; Rahman et al., 2014). Moreover, quantile regression for
censored data has been proposed as a tool to evaluate additive interaction in survival analysis
(Bellavia et al., 2016), and to estimate conditional and marginal survival curves (Bellavia et al.,
2015a).
Lastly, we recently proposed to use quantile regression for censored data — and in particu-
lar Laplace regression — as a flexible and intuitive approach to estimate survival percentiles
of age at the event (for example, age at prostate cancer death). This extends the use of this
statistical tool, especially in epidemiologic research. In fact, investigators are often more inter-
ested in describing the distribution of age at the event for a group of individuals rather than
the distribution of time elapsed between some arbitrary baseline event (for example, filling in
a questionnaire) and the occurrence of a disease (Paper II).
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2.2.4 Risk and rate advancement periods
One of the most interesting features of quantile regression is probably that the exposure-
outcome association is expressed in the metric of time as PDs. Other methods have been
proposed in the literature to express the impact of an exposure on the time of disease onset,
such as risk and rate advancement periods (RAP) or ‘expected years of (disease-free) life lost’.
RAP, in particular, was introduced by Brenner, Gefeller, and Greenland (1993) to measure
the age difference at which exposed subjects reach the same rate/risk as unexposed subjects,
assuming a monotonic increase in event rate/risk over age, independence of the outcome of
interest from competing risks, and conditional on disease-free survival to some baseline age. In
this section we will refer to the rate advancement period only.12 The risk advancement period
is defined in a similar fashion and is presented in Paper III.
This measure has been recently given special attention by the CHANCES consortium,13
which is an international pooling project of primary data from cohort studies [including the
Cohort of Swedish Men (COSM), see section 4.1] (Boffetta et al., 2014). The quantification
of RAP to assess the impact of health-related characteristics on chronic diseases (including
cancer) and overall mortality is the principal research aim of published papers (Mons et al.,
2015; Müezzinler et al., 2015) and research proposals (Orsini, personal communication).
Definition
Suppose one wants to assess in a cohort study the association between an exposure e and the
rate R of a binary event of interest d. Let h(a, e,c) be the hazard of the outcome d at baseline
age a among those at exposure level e with a fixed covariate vector c = (c1, . . . , ck). Suppose
also that one is interested in two fixed exposure levels in particular, say e0 and e1. For any
given baseline age a1, the idea behind the RAP is to seek the earliest age a0 such that:
h(a0, e0,c) = h(a1, e1,c). (2.17)
If an a0 satisfying the preceding equation exists, one can define the difference in baseline
ages a0   a1 as the RAP among e1-exposed as compared with e0-exposed, starting from the
baseline age a1. The existence of a unique value a0 (and therefore the uniqueness of RAP) is
guaranteed by the assumption that the hazard function of d increases monotonically with age,
given e and c.
For example, if RAP is equal to 20 years starting from a baseline age of 40 years, then
e1-exposed individuals that were 40 years of age at baseline experienced the same rate of the
disease than e0-exposed subjects who were 60 years of age at baseline.
12To be consistent with the previous sections, the notation used in this thesis is slightly different from that used
in Paper III.
13http://www.chancesfp7.eu
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The form of risk and rate advancement periods under PH models
RAP can be estimated parametrically directly from PH models. In fact, by taking the logarithm
of both sides of equation 2.4, one obtains:
log [h(t|x)] = log⇥h0(t)⇤+ x>  = log⇥h0(t)⇤+  1e+  2g(a) + kX
i=1
 i+2ci , (2.18)
where g(·) is a smooth, monotonically increasing function of baseline age. The usual default
transform of age is the identity function g(a) = a.
Under the assumptions previously introduced, a group of e1-exposed individuals who have
a certain rate at baseline age a1 would be expected to have reached the same rate at age a0,
had they been e0-exposed, given that all the other covariates c are kept constant. Therefore,
according to (2.18),
log
⇥
h0(t)
⇤
+  1e1 +  2g(a1) +
kX
i=1
 i+2ci = log
⇥
h0(t)
⇤
+  1e0 +  2g(a0) +
kX
i=1
 i+2ci
 1e1 +  2g(a1) =  1e0 +  2g(a0).
(2.19)
Thus, if e1  e0 = 1,  2 6= 0, and g(·) is the identity function,
RAP= a0  a1 =  1 2 , (2.20)
which is the RAP for a 1-unit increase in e, expressed in the time scale of a (for example years,
if baseline age is expressed in years).
Note that if g(·) is not the identity function, RAP is no longer constant over baseline age
and it will depend on a1. For example, if g(a) = log(a), RAP becomes
RAP(a1) = a0  a1 =

exp
✓
 1
 2
◆
  1
 
a1. (2.21)
Unfortunately, this measure has been misinterpreted in studies, commentaries, and edi-
torials published in major epidemiologic and medical journals. Moreover, important aspects
regarding RAP estimation have often been overlooked. These aspects are covered in detail in
Paper III.
2.3 Dose–response meta-analysis of aggregated data
Individual epidemiologic studies on primary data usually report study findings regarding the
dose–response association between a quantitative exposure and the risk of a binary disease in
tabular form, as exemplified by table 2.3. The results presented in this fashion are obtained
by categorizing the quantitative exposure in J + 1 levels, which are then modeled with indi-
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cator variables keeping one exposure level as referent. The exposure-outcome association is
expressed in terms of J category-specific RRs.
Generally, access to primary data for all the K studies investigating a certain exposure-
disease association is not possible. As a consequence, the only way to synthesize the existing
information on the overall shape of the dose–response association, and to examine whether
this shape is modified by study-level characteristics, is to use aggregated (summarized) data
coming from the aforementioned study-specific tables.
The common approach to dose–response meta-analysis is based on a two-stage procedure.
In the first stage the dose–response associations are estimated for each of the K studies, while
in the second stage the study-specific parameters defining the dose–response relations are
combined using methods for multivariate meta-analysis.
2.3.1 First stage: study-specific dose–response models
Study-specific regression models
In the first stage, for each of the K studies included in the meta-analysis (i = 1, . . . ,K), the
dose–response relation between the quantitative exposure and the log–relative risks (logRRs)
is estimated based on the published aggregated data (Greenland and Longnecker, 1992; Berlin
et al., 1993; Orsini et al., 2006). This is done by means of the following linear model:
yi = Xi  i + ✏i . (2.22)
The vector yi contains the logRR estimates for all the Ji non-referent exposure categories,
while Xi is the (Ji⇥q) design matrix containing the assigned doses relative to the non-referent
exposure categories and/or some flexible dose transformations. Specifically, the design matrix
Xi is defined as follows:
Xi =
26664
g1(xi1)  g1(xi0) · · · gq(xi1)  gq(xi0)
...
...
g1(xiJi )  g1(xi0) · · · gq(xiJi )  gq(xi0)
37775 .
Table 2.3: Aggregated dose–response data for the i-th study
Exposure level Assigned dose Cases na RR 95% CI
0 xi0 ci0 ni0 1 (ref)
1 xi1 ci1 ni1 RRi1 RRi1,RRi1
...
...
...
...
...
...
Ji xiJi ciJi niJi RRiJi RRiJi , RRiJi
a Depending on the study design, this column reports person-years, total number of
subjects, or number of non-cases.
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For example, for a simple linear trend (q = 1)
Xi =
26664
xi1  xi0
...
xiJi   xi0
37775 ,
while for a quadratic polynomial model (q = 2)
Xi =
26664
xi1  xi0 x2i1  x2i0
...
...
xiJi   xi0 x2iJi   x2i0
37775 .
Note that the design matrix does not include the intercept, as the logRR for the referent
exposure value x0i is equal to 0 (RR = 1) — that is, the regression line must pass trough
the origin. It is also important to underline the absence of the subscript i from the exposure
transformation functions g1(·), . . . , gq(·). This is because the same exposure transformations
must be used for all the K studies, as it will become apparent later on, when discussing the
second stage.
Lastly,   i is a vector of unknown regression coefficients of length q, defining the study-
specific dose–response association.
Approximation of the covariances between log–relative risks
The error terms ✏i are heteroskedastic, as the individual logRRs are not estimated with equal
precision. Furthermore, a particular characteristic of model (2.22) is that the error terms are
correlated, since the non-referent logRRs share a common reference group. This implies that
the variance-covariance matrix of the error terms for the i-th study is equal to the following
symmetric matrix
Cov(✏i) = Si =
2666666664
 2i11
...
. . .
 i j1  
2
i j j
...
. . .
 iJi1 · · ·  iJi j · · ·  2iJi Ji
3777777775
.
Generally, the covariances between logRRs will be different from zero, and two different
methods to approximate them using aggregated data only have been proposed (Greenland
and Longnecker, 1992; Hamling et al., 2008). These methods require information about the
number of cases and, depending on the study design, person-years/number of subjects/number
of non-cases for each exposure level. An empirical evaluation of these approximations and a
comparison between their underlying assumptions have been presented by Orsini et al. (2012).
Lastly, the variances on the diagonal can be easily back calculated from the 95% CIs for the
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RRs as
 2i j j =
24 log(RRi j)  log(RRi j)
2⇥ 1.96
352 .
Estimation
The matrix Si , which is treated as known, is used to efficiently estimate the coefficient vector   i
and its variance-covariance matrix V(  i) using the Generalized Least Squares (GLS) estimator:
 ˆ i =
Ä
X>i S 1i Xi
ä 1
X>i S 1i yi
Vˆ(  i) =
Ä
X>i S 1i Xi
ä 1
.
If one assumes independence between the logRRs, the off-diagonal elements of Si are set
to 0, and the Weighted Least Square (WLS) estimator is used to estimate   i and V(  i).
Example of di erences in results using primary data, WLS, and GLS
An example of the possible consequences related to ignoring the covariance between logRRs
is illustrated next.
The aggregated data presented in table 2.4 is based on the analysis of actual primary data,
where the association between a certain quantitative exposure and the IR of a disease was
investigated. The Incidence Rate Ratio (IRR) for every 1-unit increase in the exposure was
0.918 (95% CI: 0.868–0.971), as estimated from primary data. This is the linear trend that
one would like to “reconstruct” using only summarized data.
Setting the off-diagonal elements of S equal to 0, the IRR estimated from aggregated data
using WLS was equal to 1.066 (95% CI: 1.000–1.135), wrongly identifying the direction of
the association. On the other hand, the IRR estimated approximating the covariances and em-
ploying the GLS estimator was 0.922 (95% CI: 0.865–0.983), very close to the IRR calculated
from primary data.
Table 2.4: Example data in aggregated form as reported by a single study
Exposure category Assigned dosea Cases Person-years IRR 95% CI
< 4.2 4.0 128 21,937 1.00 (ref)
4.2–4.6 4.4 463 63,153 1.26 1.03–1.53
4.6–5.0 4.8 838 118,327 1.21 1.01–1.46
5.0–5.5 5.2 973 139,864 1.19 0.99–1.43
5.5–6.0 5.7 456 69,412 1.12 0.92–1.37
  6.0 6.3 244 43,629 0.96 0.77–1.19
a The reported assigned doses are the category-specific median values calculated from primary data.
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2.3.2 Second stage: multivariate meta-analysis
In the second stage, the estimated vectors of study-specific regression coefficients are pooled
using methods for multivariate meta-analysis (Berkey et al., 1998; van Houwelingen et al.,
2002; Jackson et al., 2010, 2011; Gasparrini et al., 2012).14
The multivariate model
The result of the first stage is a set of K vectors of regression coefficients  ˆ i of length q, and
the relative (q⇥q) estimated variance-covariance matrices Vˆ(  i). The vectors  ˆ i are now used
as outcomes in a random-effect multivariate meta-analysis model
 ˆ i ⇠ Nq
Ä
✓ , Vˆ(  i) + 
ä
. (2.23)
The marginal model shown in (2.23) has independent within- (Vˆ(  i)) and between-study
components ( ), with Vˆ(  i) +  = ⌃i. In particular, in the within-study component, the
estimated  ˆ i is assumed to be sampled with error from Nq(  i ,V(  i)) — that is, a q-variate
normal distribution where   i is the vector of true unknown dose–response coefficients for
the i-th study. On the other hand, in the between-study component,   i is assumed sampled
from Nq(✓ , ), where  is the unknown (q ⇥ q) between-study variance-covariance matrix.
The vector ✓ can be interpreted as the population-average outcome parameters, which are the
coefficients defining the population-average dose–response relation.
Some considerations regarding model (2.23) can be made. First, in contrast to the set-
ting where multivariate meta-analysis is used to analyze diagnostic test accuracy or multiple
outcomes simultaneously (Arends et al., 2003), in the present setting it is not necessary for
the model parameters to be individually interpretable, rather the pooled dose–response as-
sociation is described by their joint distribution. Second, if q = 1 the model reduces to a
univariate random-effect meta-analytical model. Third, assuming that ⌃i = V(  i) — that is,
no between-study variability — the model becomes a fixed-effect model.
Multivariate meta-regression
When the shape of the dose–response association differs according to study-level covariates
(for example, study location or study design), model (2.23) can be extended to multivariate
meta-regression (van Houwelingen et al., 2002; Gasparrini et al., 2012). This means that
the q outcomes of the second stage are modeled in terms of m study-level covariates zi =
(zi1, . . . , zim) (generally including an intercept) associated with the i-th study
 ˆ i ⇠ Nq
Ä
Zi✓ , Vˆ(  i) + 
ä
. (2.24)
The matrix Z i is a (q⇥ qm) block-diagonal matrix of full rank and is derived by taking the
14Multivariate random-effect meta-analysis was first introduced by van Houwelingen, Zwinderman, and Stijnen
(1993).
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Kronecker product between an identity matrix of dimension q (I(q)) and the vector zi, such
that
Zi
q⇥qm
= I(q)
q⇥q
⌦ z>i
1⇥m
=
26664
1 zi2 · · · zim · · · 0 0 · · · 0
...
. . .
0 0 · · · 0 · · · 1 zi2 · · · zim
37775 ,
where zi1 = 1 is the intercept term. For example, suppose that the dose–response association
is modeled using a quadratic polynomial (q = 2) and that the only study-covariate of interest
is a binary variable indicating whether the i-th study was conducted in Sweden [zi = (1,1)]
or not [zi = (1,0)]. The matrix Zi for a study conducted in Sweden is therefore
Zi = I(2)⌦ z>i =
241 0
0 1
35⌦ (1,1) =241 1 0 0
0 0 1 1
35 ,
while for a study conducted elsewhere it is
Zi = I(2)⌦ z>i =
241 0
0 1
35⌦ (1,0) =241 0 0 0
0 0 1 0
35 .
The coefficient vector ✓ is now of length qm and defines the association between the q
outcomes and the m study-level covariates. The q coefficients in ✓ related to the intercept terms
are interpreted as the population-average outcome parameters for those studies characterized
by a zero value of study-level covariates. The remaining (qm  q) coefficients express how the
population-average outcome parameters vary in respect to the values taken by the study-level
covariates.
Estimation
Different estimation methods have been proposed for random-effect multivariate meta-analysis,
including likelihood-based methods and method of moments. The goal is to estimate the qm
model parameters ✓ and the parameters  of the between-study variance-covariance matrix
 [q(q+ 1)/2 parameters if no structure for  is assumed].
ML estimates of ✓ and  can be obtained simultaneously by numerically maximizing
the log-likelihood function of the marginal model (2.24), subject to the constraint that  is
positive semi-definite (White, 2011). Under the common assumption that the K studies are
independent, the log-likelihood function is proportional to the logarithm of the product of K
q-variate normal densities:
l(✓ , ;  ˆ i , Vˆ(  i),Zi) =  12
KX
i=1
log |⌃i |  12
KX
i=1
hÄ
 ˆ i   Zi✓
ä>
⌃ 1i
Ä
 ˆ i   Zi✓
äi
. (2.25)
Assuming that the elements of  are known, the parameter vector ✓ and its accompanying
variance-covariance matrix V(✓ ) can be estimated, conditional on  , by maximizing (2.25).
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In this case, closed-form equations are given by the GLS estimator
✓ˆ =
 
KX
i=1
Z>i Vˆ(  i) 1Zi
! 1 KX
i=1
Z>i Vˆ(  i) 1 ˆ i (2.26)
Vˆ(✓ ) =
 
KX
i=1
Z>i Vˆ(  i) 1Zi
! 1
. (2.27)
To avoid the downward bias of ML estimates of  , the parameters of the between-study
variance-covariance matrix can be estimated using Restricted Maximum Likelihood (REML)
(White, 2011). This bias is due to the fact that ML does not account for the loss of degrees of
freedom from the estimation of ✓ . REML estimation is carried out by iteratively maximizing
the following restricted log-likelihood, which is a function of  only and is proportional to:
lREML( ;  ˆ i , Vˆ(  i),Zi , ✓ˆ ) =  12
KX
i=1
log |⌃i |  12 log
     KX
i=1
Z>i ⌃ 1i Zi
    
  1
2
KX
i=1
hÄ
 ˆ i   Zi ✓ˆ
ä>
⌃ 1i
Ä
 ˆ i   Zi ✓ˆ
äi
,
where ✓ˆ is obtained from (2.26).
Lastly, a less computationally intensive method for multivariate meta-analysis is based on
the extension of the univariate method of moments proposed by DerSimonian and Laird (1986)
to the multivariate scenario (Jackson et al., 2010). Moreover, since the estimating procedure
for the parameters of is based on moments arguments only, the assumption of between-study
normality is not necessary.
Note that if one assumes that ⌃i = V(  i), the parameter vector ✓ and its variance-
covariance matrix V(✓ ) can be estimated using (2.26) and (2.27), repsectively.
Between-study heterogeneity
Meta-regression can be employed to identify sources of variation in study findings and for
this reason it can help explaining heterogeneity in the dose–response associations across
studies. The hypothesis of no heterogeneity between studies beyond that explained by sampling
variability and study-level covariates can be tested by means of the multivariate extension of
the Cochran Q test (Ritz et al., 2008; Jackson et al., 2012). Formally, the null hypothesis is
H0 : = 0 and the test statistic is defined as
Q =
KX
i=1
hÄ
 ˆ i   Zi ✓ˆ
ä>
Vˆ(  i)
 1 Ä ˆ i   Zi ✓ˆäi , (2.28)
where ✓ˆ is estimated using a fixed-effect model. Under the null hypothesis, the Q follows
asymptotically a chi-square distribution with (Kq   qm) degrees of freedom. This statistic
reduces to the classic Q statistic if q = 1 (Cochran, 1954).
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Furthermore, the multivariate extension of the I2 statistic proposed by Jackson et al. (2012)
can be used to measure the percentage of total variability attributable to between-study het-
erogeneity, analogously to the univariate case (Higgins and Thompson, 2002). The I2 index is
defined as
I2 =max
✓
0,
Q  (Km  qm)
Q
◆
⇥ 100%. (2.29)
Both the Q test and the I2 index have some limitations. The Q test, in particular, has been
shown to suffer from low power when the number of studies is small or the “total information”
is limited (Hardy and Thompson, 1998). On the other hand, the I2 has been criticized for
being dependent on precision of the estimates from the first-stage regression models (Rücker
et al., 2008).
Prediction of the population-average dose–response association
The prediction of the population-average dose–response association is a crucial step to display
the results in tabular and in graphical form. In particular, the goal is to present how the risk
of the disease varies according to levels of the quantitative exposure, choosing a particular
exposure value as the referent (for example, a specific BMI value or no alcohol consumption).
Moreover, in the presence of study-level covariates, one is interested in showing how they
modify the overall dose–response association.
Let X be the (v⇥q) first-stage design matrix evaluated at an arbitrary number v of exposure
doses, and let Xref be the same design matrix evaluated at the chosen reference level. Further-
more, let z be the (m⇥ 1) vector containing the study-level covariates fixed at a particular
level. The (v⇥1) vector of predicted RRs conditional on a certain study-level covariate pattern
is given by ”RR
v⇥1 = exp
24Ç X
v⇥q Xrefv⇥q
å 
I(q)⌦ z>
q⇥qm
!
✓ˆ
qm⇥1
35 .
The 100(1   ↵)% confidence interval for the predicted pooled dose–response curve is
obtained as
exp
®
log
Ä”RRä± z1  ↵2 diagh  X Xref Z  Vˆ(✓ )  X Xref Z >i 12
´
,
where Vˆ(✓ ) is the (qm⇥ qm) estimated variance-covariance matrix relative to ✓ˆ , and z1 ↵/2 is
the (1 ↵/2) quantile of a standard normal distribution.
Goodness of fit
The last step of a dose–response meta-analysis should be the evaluation of its goodness of
fit. However, despite the importance of assessing whether the posited dose–response models
provide an adequate description of the available aggregated data, this is rarely, if ever, done
in practice. Paper V will present 3 tools to evaluate the goodness of fit of a dose–response
meta-analysis, while taking into account the correlation among the logRRs.
Chapter 3
Aims of the thesis
The overall aims of this thesis were to investigate the association between BMI and prostate
cancer incidence and mortality, and to address specific methodological issues related to the
analysis of primary and aggregated data.
More specifically, the aims were:
• To assess the association between BMI during middle-late adulthood and during early
adulthood and localized/advanced prostate cancer incidence andmortality in a population-
based cohort of Swedish men.
• To summarize the existing epidemiologic evidence on the association between BMI
during middle-late adulthood and the incidence of prostate cancer by subtype of the
disease.
• To extend the use of quantile regression for censored data, and in particular of Laplace
regression, to those situations where the time scale of interest is attained age at the event
instead of follow-up time.
• To discuss how RAP has been misinterpreted in the epidemiologic literature and to show
how RAP is profoundly sensitive to the specification of disease dependence on age.
• To present and discuss relevant methods to evaluate the goodness of fit of dose–response
meta-analyses of binary outcomes.
Chapter 4
Materials and methods
Paper I and the additional results for Paper II presented in this thesis are based on the
population-based longitudinal COSM study. The meta-analysis in Paper IV is based on ag-
gregated data extracted from studies identified through a search of computerized databases,
and by reviewing reference lists.
4.1 The Cohort of Swedish Men
The principal aim of the COSM15 is to investigate the relations between a number of lifestyle
and diet factors and the incidence of several chronic diseases, including cancer (Harris et al.,
2013).
The population-based COSM was established in the fall 1997, when all men born between
1918 and 1952 residing in Västmanland and Örebro counties in central Sweden (n= 100303)
received an invitation to participate in the study, along with a self-administered questionnaire.
This questionnaire included questions about height, current body weight, body weight across
the life course (at ages 20, 30, 40, 50, 60, and 70), education, physical activity (at ages 15, 30,
50, and current), smoking habits, family history of prostate cancer, and diet.
A total of 48,850 men returned the questionnaire (49%). After excluding those participants
who reported an incorrect/incomplete personal identificaiton number (n= 205),16 returned
an incomplete questionnaire (n= 92), died before 1 January 1998 (n= 55), or had a prevalent
cancer diagnosis (except non-melanoma skin cancer) (n= 2592), the final cohort consisted of
45,906 men. The follow-up period started the 1st of January 1998.
The COSM is comparable to the general Swedish population of men aged 45–79 years in
1997 with regards to age distribution, education level, and proportion of overweight (BMI >
25 kg⇥m 2) (see table 4.1, reproduced from Harris et al., 2013).
The protocol of this study has been approved by the relevant ethical committee. All subjects
gave full informed consent to participate in this study.
15https://clinicaltrials.gov/ct2/show/NCT01127711
16The number of men who returned the questionnaire reported in Paper I is equal to 48645= 48850  205.
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Table 4.1: Comparison of the COSM with the Swedish male population aged 45–79
years in 1997, regarding age distribution, educational level, and proportion of over-
weight (Harris et al., 2013).
COSM study population
aged 45–79 years in 1997
Swedish male population
aged 45–79 years in 1997a
Age groups (years)
Total (n) 45,906 1,594,952
45–49 (%) 15.9 19.5
50–54 (%) 18.8 20.8
55–59 (%) 15.9 15.6
60–64 (%) 13.1 12.5
65–69 (%) 14.1 11.6
70–74 (%) 12.4 10.8
75–79 (%) 9.9 9.2
Education, ages 48–74 yearsb
Total (n) 41,382 144,585
 12 years (%) 82.3 77.1
>12 years (%) 17.3 21.0
Overweight (BMI >25 kg⇥m 2), by age groups (years)
45–54 (%) 54.5 57.2
55–64 (%) 59.1 60.3
65–74 (%) 59.8 57.0
75–84 (%) 47.5 43.0
a Data from SCB.
b Educational level reported are for those  74 years of age since data from SCB were not
available for older ages.
4.2 The national registers
4.2.1 The Swedish Cancer Register
The Swedish Cancer Register (SCR), maintained by the NBHW, was founded in 1958 and covers
the whole population in Sweden. Epidemiologic research is one of the specific objectives of this
register. The information available from the SCR includes patient data (personal identification
number, age, sex, and residence), medical data (tumor site, histological type, and date of
diagnosis), and follow-up data (including date and cause of death). Health care providers are
obliged by law to report newly diagnosed cancers to the SCR. Completeness of this register
was observed to be high (Barlow et al., 2009).
4.2.2 The National Prostate Cancer Register
From 1998 the NPCR includes all the incident cases of prostate adenocarcinomas diagnosed
in Sweden. One of the primary aims of the NPCR is to provide data for clinical research. This
register includes detailed information on tumor stage (according to the TNM staging system),
Gleason score, and PSA serum level at diagnosis (van Hemelrijck et al., 2013). It has been
estimated that, during the period 1998–2012, a total of 98% of men diagnosed with prostate
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cancer registered in the SCR had also been registered in the NPCR (Tomic et al., 2015).
4.2.3 The Cause of Death Register
Starting from 1953, the NBHW maintains the Cause of Death Register (CDR). This register
contains information on the date and underlying cause of death of all Swedish citizens, irre-
spective of whether they died in Sweden or abroad. The CDR is complete from 1 January 1969.
The reliability of official cause-of-death statistics of prostate cancer patients in Sweden was
observed to be reasonably high (Fall et al., 2008; Godtman et al., 2011).
Deaths whose underlying cause was attributed to prostate cancer (code 61 according to
the International Classification of Diseases, 10th revision) are equally referred to in this thesis
as ‘prostate cancer deaths’ or ‘fatal prostate cancer’.
4.3 Description of COSM data and comparison with Swedish
national data
In this section we will describe prostate cancer incidence and mortality in the COSM and will
compare the results with Swedish national data.
4.3.1 Prostate cancer incidence
Prostate cancer incidence in the COSM
To date, the most recent available data at the Unit of Nutritional Epidemiology (Institute of
Environmental Medicine, Karolinksa Institutet) include information on incident prostate cancer
cases from 1 January 1998 until 31 December 2012 (SCR data). Data regarding tumor stage,
Gleason score, and PSA levels are available until 31 December 2011 (NPCR data).
During 15 years of follow up (1998–2012), a total of 4,213 newly diagnosed cases were
identified. Figure 4.1 illustrates prostate cancer IRs by attained age and calendar year in the
COSM. In particular, the solid lines are the predicted IRs from a single ‘flexible’ PH model,
where attained age was modeled using Restricted Cubic Splines (RCS) with 3 knots placed at
the 10th, 50th, and 90th percentiles of the distribution of uncensored times (corresponding to
61, 72, and 82 years of age) (Harrell, 2001). Moreover, the age-incidence curves were allowed
to vary their shape across calendar year — that is, the IRs between calendar years were not
forced to be proportional. The hollow circles represent the observed IRs by 5-year categories of
attained age (45–49, 50–54, . . . , 80–84, and 85+) and calendar year (1998,. . . ,2012). Their
size is proportional to the precision (inverse of the variance, assuming a Poisson distribution)
of the estimate. As expected, the IRs increased steeply after 55–60 years of age, peaked around
the age of 75 years, and generally declined thereafter.
As noted in section 2.1.1, prostate cancer incidence shows large geographical variation even
within Sweden (Stattin et al., 2005; Jonsson et al., 2011). This could be partly due — despite
a uniform, equal-access health-care system — to between-county differences in PSA-screening
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uptake (Jonsson et al., 2011). Interestingly, the COSM study recruited participants from one
high-incidence county (Västmanland) and one low-incidence county (Örebro) (Stattin et al.,
2014). Not surprisingly, the age-adjusted prostate cancer IR was observed to be 16% higher
among those men residing in Västmanland county at the time of enrollment as compared with
those residing in Örebro county, marginally over the 15 years of follow-up [IRR: 1.16 (95%
CI: 1.09–1.23)]. Figure A.1 in the appendix shows the model-based predicted IRs by attained
age, calendar year, and county of enrollment. The ratio between directly age-standardized
IRs for Västmanland versus Örebro county was observed to be around 1.21 during the period
2000–2001, based on registry data (Stattin et al., 2005, table I).
Comparison with Swedish national data
To the best of my knowledge, the only comparison between COSM and Swedish data in terms of
prostate cancer incidence was carried out by Orsini (2008, section 5.4) in his PhD thesis. That
analysis, which showed a remarkable good agreement between COSM and Swedish national
data, was however limited to year 1998 only.
Information about the number of incident prostate cancer cases by 5-year classes of age
(a = 1, . . . , 9 = “45–49”,. . . ,“85+”) and calendar year (c = 1998, . . . , 2012) was available
from the NBHW website (da,c),17 while the total number of men for the same categories was
available from the SCB website (Na,c).18 Under the assumption of constant prostate cancer
incidence within age and calendar-year categories, the corresponding IRs in the Swedish male
population were calculated as
h⇤a,c =   log
0B@1  da,c
Na,c   da,c2
1CA .
Standardized Incidence Ratios (SIRs) were obtained comparing the observed number of
incident prostate cancer cases in the COSM with the expected number of cases obtained by
applying Swedish national rates to the COSM age and calendar-year structure (Breslow and
Day, 1987, section 2.3). The overall SIR was calculated as follows:
SIR·,· =
9P
a=1
2012P
c=1998
oa,c
9P
a=1
2012P
c=1998
h⇤a,c ta,c
=
9P
a=1
2012P
c=1998
oa,c
9P
a=1
2012P
c=1998
ea,c
,
where oa,c was the number of observed cases, ta,c the total person-years in the COSM, and ea,c
the number of expected cases. Marginal SIRs over attained age or calendar year were calculated
by summing over the appropriate index (which, following standard notation, is replaced by
a dot). Lastly, SIRs conditional on both attained age and calendar year were calculated as
17http://www.socialstyrelsen.se/statistik/statistikdatabas/cancer/
18http://www.scb.se/sv_/Hitta-statistik/Statistik-efter-amne/Befolkning/
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SIRa,c = oa,c/ea,c, for a given combination of a and c. Exact confidence intervals for the SIR
can be calculated, under the assumption that the observed number of cases follows a Poisson
distribution, using the formulae provided by Ulm (1990), or directly from the Poisson p.d.f.
by the Newton-Raphson method. Alternatively, the number of observed cases can be modeled
as a flexible function of a number of covariates (in this case, calendar year and attained age).
This can be done by means of, among different methods, a multiplicative Poisson regression
model — that is, a Generalized Linear Model with logarithmic link and Poisson distribution
for the outcome — with an offset term containing the expected number of cases (Berry, 1983;
Breslow and Day, 1987).
Table B.1 in the appendix reports the number of observed (top entry) and expected (bottom
entry) prostate cancer cases according to attained age categories and calendar year in the
COSM. Overall — that is, marginally over categories of attained age and calendar year — the
SIR·,· for prostate cancer was equal to 4213/3656= 1.15 (95% exact CI: 1.12–1.19).
Figure 4.2 shows the observed SIRs (hollow circles) calculated marginally over categories
of attained age (panel A), and over calendar year (panel B). Furthermore, in panel A, SIR was
modeled as a function of calendar year using RCS with 4 knots at years 1999, 2003, 2007, and
2012 (solid line). Similarly, panel B exhibits SIR modeled as a function of attained age using
RCS with 4 knots at ages 55, 65, 75 and 80 years (solid line).
There was no evidence of an association between calendar year and SIR in the RCS model
(poverall = 0.21) or in a simpler linear model (plinear = 0.88). Note how the SIR relative to
1998 was very close to 1 [SIR·,1998 = 168/173 = 1.03 (95% exact CI: 0.88–1.19), see table
B.1], in line with what observed by Orsini (2008). Conversely, attained age was observed to
be associated with SIR in the RCS model (poverall < 0.001), with evidence of non-linearity
(pnon-linearity = 0.002), indicating evidence of an increased SIR at older ages as compared with
younger ages.
Lastly, the SIR calculated only among those men enrolled in Västmanland county was equal
to 2223/1792= 1.24 (95% exact CI: 1.19–1.29), while it was 1990/1865= 1.07 (95% exact
CI: 1.02–1.11) for those men enrolled in Örebro county (pheterogeneity < 0.001).
4.3.2 Prostate cancer mortality
Prostate cancer mortality in the COSM
Between 1 January 1998 and 31 December 2012, a total of 691 deaths whose underlying
cause was attributed to prostate cancer were observed in the COSM (CDR data). Figure 4.3
shows prostate cancer MRs by attained age and calendar year. The solid lines are the model-
based MRs from a ‘flexible’ PH regression model, where attained age was modeled using RCS
with 3 knots at 67, 80, and 87 years of age. The PH assumption was once again relaxed via
time-dependent coefficients for calendar year.
The interpretation of the analysis on prostate cancer mortality is affected by the fact that
the COSM is a cohort of cancer-free men at baseline. In fact, as described previously, all men
with a prevalent cancer diagnosis at baseline were excluded from the study. It is therefore not
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Figure 4.2: SIRs of prostate cancer by calendar year (panel A) and attained age (panel B). The solid
lines are model-based predicted SIRs, while dashed lines are 95% confidence intervals. The hollow
circles represent the observed SIRs by 5-year groups of attained age and calendar year together with
95% confidence intervals. The confidence interval for SIR1,· was not displayed since extremely wide, as
it was based on 1 case only (see table B.1). The vertical axes are on the natural log scale.
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surprising that the prostate cancer MRs were very low during the first years of follow-up, even
at older ages. For example, in 1998 only 2 deaths due to prostate cancer were observed. On
the other hand, during the last years of follow-up, the mortality curves showed a very steep
increase at older ages, in line with what one would expect.
Over the 15 years of follow-up, the MR was shown to be 9% lower among those men
residing in Västmanland county at baseline as compared with those men residing in Örebro
county [Mortality Rate Ratio (MRR): 0.91 (95% CI: 0.78–1.06)]. Similarly, restricting the
analysis to the last 6 years of follow-up (2007–2012, 406 prostate cancer deaths), the MRR
was observed to be 0.88 (95% CI: 0.72–1.07).
The lower prostate cancer–specific mortality19 observed in Sweden by Stattin et al. (2014)
in high-incidence counties as compared with low-incidence counties, among men aged 50–74
years and during the years 2000–2009 [RR: 0.87 (95% CI: 0.81–0.95)], was similar to that
observed between Västmanland and Örebro counties in the COSM [prostate cancer–specific
MRR: 0.85 (95% CI: 0.73–0.99)].
Comparison with Swedish national data
Comparison of prostate cancer MRs between COSM and Swedish national data was carried
out in terms of Standardized Mortality Ratios (SMRs). Source of Swedish data, statistical tools,
and notation are identical to those described in section 4.3.1.
Table B.2 reports the number of observed (top entry) and expected (bottom entry) prostate
cancer deaths in the COSM according to attained age categories and calendar year. Overall,
SMR·,· = 691/1034= 0.67, with 95% exact CI equal to 0.62–0.72. Again, this is not surprising
given that the comparison was made between two populations, one of which was cancer-free
at baseline while the other one was not.
Figure 4.4 shows the observed SMRs by calendar year calculated marginally over categories
of attained age (hollow circles), as well as the SMR modeled as a function of calendar year
using RCS with 4 knots positioned at years 1998, 2002, 2007, and 2012 (solid line). In the RCS
model, there was evidence of an association between calendar year and SMR (poverall < 0.001)
and also of non-linearity (pnon-linearity < 0.001). The observed SMRs were as low as 0.05 in
1998 [SMR·,1998 = 2/43 = 0.05 (95% exact CI: 0.01–0.17)], and increased over calendar
year to level off after, say, year 2004/2005, not far from the value of 1. At the same time, no
systematic variation in SMR was observed when modeled as a function of attained age (figure
A.2).
One might have expected a longer time period before the SMRs approached values closer
to 1, given the long latency of prostate cancer. However, the COSM was ‘cancer-free at baseline’
only in the sense that those men with a prevalent cancer diagnosis were excluded. Therefore,
men with an undiagnosed prostate cancer were still included in the cohort. This can have
contributed to a relatively shorter period before the prostate cancer MRs in the COSM reached
19Prostate cancer–specific mortality refers to mortality due to prostate cancer among men diagnosed with the
disease.
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comparable levels to those observed in Sweden.
Lastly, considering the years 2006–2012 only, there was no evidence that the SMR for
those men enrolled in Västmanland county [SMR·,2006–2012 = 210/278= 0.75 (95% exact CI:
0.66–0.86)] was different from that for those men enrolled in Örebro county [SMR·,2006–2012 =
251/289= 0.87 (95% exact CI: 0.76–0.98)] (pheterogeneity = 0.14).
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Figure 4.4: SMRs of prostate cancer by calendar year. The solid line is the model-based predicted SMR,
while dashed lines are 95% confidence intervals. The hollow circles represent the observed SMRs by
calendar year together with 95% confidence intervals. The confidence interval for SIR·,1998 was not
displayed since extremely wide, as it was based on 2 deaths only (table B.2). The vertical axis is on the
natural log scale.
4.4 Paper I
Exposure assessment
BMI during early adulthood was calculated as recalled weight (in kilograms) at the age of
30 years multiplied by self-reported height (in meters) to the power of minus 2. In a similar
fashion, BMI during middle-late adulthood was computed from the self-reported weight at
baseline — that is, at ages 45–79 years — and self-reported height. In addition to the exclusions
described in section 4.1, we excluded those men with BMI at baseline or at 30 years of age
outside the range 15–40 kg⇥m 2 (n= 196) or missing (n= 8751), leaving thus 36,959 men
for the analyses.
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Outcome assessment
Incident cases of prostate cancer were ascertained by linkage with the SCR, while linkage
with the NPCR provided data regarding TNM staging, Gleason score, and PSA serum level at
diagnosis. Prostate cancer cases were classified by subtype of the disease either as localized [T1–
2 and Nx–0 and (Mx–0 or PSA < 20 ng⇥ml 1 or Gleason score 2–7)] or advanced [T3–4 and
Nx–1 and (Mx–1 or PSA > 100 ng⇥ml 1 or Gleason score 8–10)]. These classification criteria
do not exactly match with those used by the NPCR (2013). Nevertheless, the definition of
localized cases is comparable to the combination of ‘low-risk’ and ‘intermediate-risk’ categories,
whereas the definition of advanced cases is comparable to the combination of ‘regionally
metastatic’ and ‘distant metastases’ categories (table 2.1). Information on prostate cancer
deaths was obtained from the CDR.
From 1 January 1998 to 31 December 2008, during 371,792 person-years, a total of 1,530
localized and 554 advanced cases were identified. From 1 January 1998 to 31 December 2007,
during 333,702 person-years, 225 cases of prostate cancer death were documented.
Statistical analysis
Cox PH models were used to examine the multivariable-adjusted association of both BMI at 30
years of age and BMI at baseline age with the IR or MR of prostate cancer, as appropriate. The
exposures were modeled as continuous variables and second-degree Fractional Polynomials
(FP2) (Royston et al., 1999) were employed whenever this provided a better overall fit of
the model, as measured by the Akaike Information Criterion (AIC). The value of 22 kg⇥m 2
was used as the referent. Models were adjusted for age (years), total energy intake (kcal),
total physical activity (<37.9, 38.0–40.9, 41.0–44.9,  45.0 MET-h/day), education (years),
smoking status (current, former, never smoker), family history of prostate cancer (yes, no, don’t
know), and personal history of diabetes (yes, no).
Updated analysis
In section 5.1.2, we present updated analyses using the most recent data available at our Unit
to take advantage of the extended follow-up period.
The number of subjects in the study (n= 36959) and the classification criteria for localized
and advanced subtypes of prostate cancer were left unchanged. The follow-up was extended
until 31 December 2011 for incidence of prostate cancer subtypes, and until 31 December 2012
for prostate cancer mortality. During 456,322 person-years, a total of 2,078 localized cases
and 727 advanced cases were identified. On the other hand, during 500,765 person-years, 508
deaths attributed to prostate cancer were documented.
Multivariable-adjusted Cox PH models, similar to those previously described, were em-
ployed. In these updated analyses, however, the baseline hazard was allowed to vary between
counties of residence at baseline (Västmanland/Örebro) by means of stratified Cox models
(van Houwelingen and Stijnen, 2013). Results were presented in tabular form by categorizing
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BMI in 6 groups: < 21.0, 21.0–22.9 (referent), 23.0–24.9, 25.0–27.4, 27.5–29.9, and   30.0
kg⇥m 2.
In the analysis on localized prostate cancer, BMI at baseline age was again modeled using
FP2. Moreover, RCS with 4 knots placed at the 5th, 35th, 65th, and 95th percentiles of the
distributions of BMI at baseline age and of BMI at age 30 years were also employed for all
the analyses.20 Lastly, we examined whether the associations differed according to county of
residence at baseline by including appropriate product terms in the Cox models.
4.5 Paper IV
Literature search and study characteristics
Identification of the studies reporting information about the association between BMI and inci-
dence of localized and advanced prostate cancer was done by searching the Medline (PubMed)
and Embase databases. The search query was the following: (obesity or BMI or “body size” or
adiposity) and “prostate cancer”. Moreover, reference lists from reviews and other relevant
publications were reviewed to identify further studies to be included in the meta-analysis.
Lastly, effort was put in the identification of possible studies not included in the computerized
databases.
A total of 15 articles were left after the exclusion of case-control studies (n= 54), studies
not reporting results separately by prostate cancer subtypes (n= 16), and duplicate studies on
the same population (n= 2). In addition, 2 out of these 15 studies were excluded because did
not report the number of cases and person-years per BMI category (Habel et al., 2000; Gong
et al., 2006), which is necessary to approximate the study-specific variance-covariance matrix
Si .
Consequently, 13 prospective studies were available for the analyses (Cerhan et al., 1997;
Giovannucci et al., 1997; Putnam et al., 2000; Schuurman et al., 2000; MacInnis et al., 2003;
Kurahashi et al., 2006; Littman et al., 2007; Rodriguez et al., 2007; Wright et al., 2007; Pischon
et al., 2008; Wallström et al., 2009; Stocks et al., 2010; Discacciati et al., 2011), 1 of which
reported results only for advanced prostate cancer (Giovannucci et al., 1997), leaving thus
12 articles for the meta-analysis on localized prostate cancer. A flowchart summarizing the
identification of relevant studies is shown in Paper IV, figure 1, while detailed information
about the single studies is available in Paper IV, supplemental table S1.
The 12 studies on localized prostate cancer, published during the period 1997–2011, in-
volved a total of 1,033,009 men and 19,130 incident cases. Five of these studies were con-
ducted in the U.S., 3 in Sweden, 1 in the Netherlands, 1 in Australia, 1 in Japan, and 1 was
an European multi-centre study. Four studies relied on trained personnel to collect weight
and height, while the remaining 8 studies were based on self-reported measurements. Lastly,
three studies provided RR estimates adjusted for both physical activity and personal history of
20Corresponding to knots placed at 20.9, 24.3, 26.5, and 31.6 kg⇥m 2 for BMI at baseline age, and at 19.4, 22.1,
23.8, and 27.4 kg⇥m 2 for BMI at age 30 years.
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diabetes, while 9 studies adjusted only for one of these two variables or for neither.
The 13 studies on advanced prostate cancer included a total of 1,080,790 men and 7,067
newly diagnosed cases. The study that reported results only for advanced prostate cancer was
conducted in the U.S, relied on self-reported weigh and height measurements, and did not
adjust for physical activity activity or for personal history of diabetes.
Interestingly, the criteria used to classify incident prostate cancer cases as localized or
advanced were very heterogeneous. In particular, they were based on the Gleason score, World
Health Organization grading system, TNM and Jewett–Whitmore staging system, PSA level, or
different combinations of these.
Updated dose–response meta-analysis
For localized prostate cancer, the studies by MacInnis et al. (2003) [Melbourne Collaborative
Cohort Study (MCCS)] and Paper I (COSM) were superseded by Bassett et al. (2012) and by
the updated analyses presented in section 5.1.2, respectively. The study by Gong et al. (2006)
was included assuming 0 correlation between the logRRs. The study by Schuurman et al.
(2000) was excluded because it reported only a linear trend. Lastly, 2 studies not included in
Paper IV were added to the meta-analysis (Hernandez et al., 2009; Grotta et al., 2015). Thus,
a total of 14 prospective cohort studies were available for the analysis, including a total of
1,081,926 and 26,500 cases.
For advanced prostate cancer, the studies by MacInnis et al. (2003) (MCCS) and Paper I
(COSM) were superseded by Bassett et al. (2012) and by the analyses presented in section
5.1.2, respectively. The studies by Habel et al. (2000) and by Gong et al. (2006) were included
assuming that the reported logRR estimates were uncorrelated. The study by Schuurman et al.
(2000) was excluded because it reported only a linear trend. Lastly, 4 studies were added to
the meta-analysis (Hernandez et al., 2009; Shafique et al., 2012; Grotta et al., 2015; Møller
et al., 2015). In summary, the meta-analysis on advanced prostate cancer was based on 18
prospective studies including 1,240,222 men and 10,174 incident cases.
Chapter 5
Results
5.1 Paper I
In this paper we examined the association of BMI during early adulthood (30 years of age)
and middle-late adulthood (45–79 years of age) with the incidence of prostate cancer subtypes
and with prostate cancer mortality in the population-based COSM.
5.1.1 Main results
Baseline age-standardized characteristics of the study participants according to categories of
BMI during middle-late adulthood are presented in Paper I, table 1. Overweight and obese men
at baseline were more likely to have a personal history of diabetes and to be former smokers
as compared with underweight and normal-weight men. On the other hand, they were less
likely to be physically active or well-educated.
Multivariable-adjusted IRRs and MRRs according to levels of BMI at baseline age and BMI
at age 30 years are presented in Paper I, table 2, table 3, and figure 1.
For localized prostate cancer, BMI at baseline age was modeled using the best-fitting FP2
transformation, which was characterized by fractional powers ( 2, 2). This increased the
overall fit of the model as compared with modeling BMI in a linear fashion (AICFP2( 2, 2) =
36614 versus AIClinear = 36616), and conferred to the relationship between BMI at baseline
age and IR of localized prostate cancer an inverse–U shape. In particular, the IR of localized
prostate cancer at 35 kg⇥m 2 was 29% lower than that at 22 kg⇥m 2 [IRR: 0.71 (95% CI:
0.53–0.94)], while the IR at 18 kg⇥m 2 was 12% lower [IRR: 0.78 (95% CI: 0.54–1.13)].
BMI at age 30 years was associated with a 2% decreased IR for every 5-unit increment [IRR:
0.98 (95% CI: 0.87–1.12)].
For advanced prostate cancer, BMI at baseline age was associated with a 4% increased IR
[IRR: 1.04 (95% CI: 0.88–1.22)], whereas BMI at age 30 years was associated with a 10%
decreased IR [IRR: 0.90 (95% CI: 0.73–1.11)], both for every 5-unit increment.
For fatal prostate cancer, BMI at baseline age was associated with a 12% increased MR
[MRR: 1.12 (95% CI: 0.87–1.43)], while BMI at age 30 years was associated with a 27%
decreased MR [MRR: 0.73 (95% CI: 0.53–1.02)], both for every 5-unit increment.
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5.1.2 Updated analyses with extended follow-up
For localized prostate cancer, BMI at baseline age showed an inverse–U association, regardless
of whether it was modeled using FP2( 2, 2) (green line), FP2( 1,0.5) (purple line),21 or
RCS (blue line) (figure 5.2). From the categorical analysis, the multivariable-adjusted IR for
the obese men at baseline (BMI  30 kg⇥m 2) was 21% lower that that for men in the referent
category (21.0–22.9 kg⇥m 2) [IRR: 0.79 (95% CI: 0.64-0.98)] (table B.3).
For advanced prostate cancer, BMI at baseline age was associated with a 11% increased
IR for every 5-unit increment [IRR: 1.11 (95% CI: 0.96–1.27)] (table B.3). No evidence of
non-linearity was observed from the RCS model (pnon-linearity = 0.30) (figure 5.2).
For fatal prostate cancer, BMI at baseline age was associated with a 12% increased MR for
every 5-unit increment [MRR: 1.12 (95% CI: 0.95–1.32)] (table B.3). Again, no evidence of
non-linearity was observed (pnon-linearity = 0.49) (figure 5.2).
No evidence against the PH assumption was observed for any of the exposure-outcome
associations. For example, figure 5.1 shows the time-varying MRR of fatal prostate cancer
for BMI at baseline age   30 kg⇥m 2 versus 21.0–22.9 kg⇥m 2, where the time-dependent
coefficient for BMI was modeled using RCS with 3 knots placed at the the 10th, 50th, and 90th
percentiles of the distribution of the uncensored event times (Discacciati et al., 2015c).22 The
p-value relative to the test against the null hypothesis H0 :  1 =  2 = 0 was equal to 0.91 [see
equation (2.8)].
Lastly, no evidence of heterogeneity by county of residence at baseline was observed, as
shown in table 5.1.
Updated results for BMI at 30 years of age are reported in table B.4 and in figure A.3.
Overall, the results based on the updated data were consistent with those reported in Paper I,
and generally more precise.
Table 5.1: Heterogeneity by county of residence at baseline (Västmanland/Örebro) in the
association between BMI at baseline age and localized, advanced, and fatal prostate cancer
BMI at baseline age
Outcome Västmanland Örebro pheterogeneity
Localized prostate cancera 0.68 (0.44–0.91) 0.74 (0.49–1.00) 0.35
Advanced prostate cancerb 1.13 (0.95–1.35) 1.08 (0.90–1.30) 0.71
Fatal prostate cancerc 1.20 (0.96–1.51) 1.05 (0.85–1.30) 0.36
a Multivariable-adjusted IRR comparing a BMI of 35 kg⇥m 2 with a BMI of 22 kg⇥m 2 from the
FP2( 2, 2) model.
b Multivariable-adjusted IRR for every 5-unit increment.
c Multivariable-adjusted MRR for every 5-unit increment.
21The best-fitting FP2 in the updated data according to AIC.
22Corresponding to 65.5, 79.8, and 87.2 years of attained age.
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Figure 5.1: Time-varying MRR from prostate cancer for BMI at baseline age   30 kg⇥m 2 versus 21.0–
22.9 kg⇥m 2 (solid black line). The dashed black lines are 95% confidence interval. The long-dashed
grey line is the time-fixed MRR, equal to 1.25 (table B.3). The vertical axis is on the natural log scale.
5.2 Paper II
In Paper II we proposed the use of Laplace regression to estimate percentiles of attained age
at the time of the event of interest. We also discussed the consequences in the interpretation
of the survival curve in the presence of delayed entries.
5.2.1 Estimating percentiles of attained age at the event
Defining the time scale
An important consideration when analyzing the distribution of survival time is the choice of
the time scale. In particular, the difference between the origin of the time scale — that is, that
point in time when the subjects become at risk of experiencing the event of interest — and the
time at which subjects start to be actually followed-up merits particular attention.
In randomized experimental studies, for example, subjects are typically considered to be-
come at risk at the time of their random allocation to either the treatment or placebo arm.
In such cases, the most natural time scale is ‘time since randomization’ (or ‘follow-up time’),
which takes value 0 at randomization. Given this sampling design, sometimes called ‘sampling
the inflow’, the start of the observation period coincides with the time at which individuals
become at risk.
In observational epidemiologic studies, on the other hand, attained age is often a more
natural time scale as compared with time since some arbitrary baseline event (Korn et al.,
1997; Thiébaut and Bénichou, 2004; Cologne et al., 2012). In this case, the time at which
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Figure 5.2: Multivariable-adjusted associations of BMI at baseline age (kg⇥m 2) with IR of localized
and advanced prostate cancer, and with MR of fatal prostate cancer in the updated analysis of Paper I.
BMI was modeled using FP2( 2, 2) (green line), FP2( 1,0.5) (purple line), RCS with 4 knots (blue
line), and in a linear fashion (red line). The referent value was set at 22 kg⇥m 2. Vertical lines above
the curves represent cases of prostate cancer. The vertical axes are on the natural log scale.
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individuals become at risk does not necessarily coincide with the start of the observation
period. This situation is referred to as ‘delayed entry’ — that is, individuals become at risk
before entering the study. Delayed entries introduce left-truncation, which means that some
subjects are excluded from the study because they either died or experienced the event before
observation began (Harrell, 2001, section 16.2; Rabe-Hesketh and Skrondal, 2012, part VII).
As a result, an extra piece of information, Tentry,i , has to be added next to Yi =min(Ti ,Ci) and
di in order to be able to describe the survival experience of the i-th individual.
In the specific case of COSM and prostate cancer, age is arguably a more meaningful time
scale than time since baseline, which corresponds to the time when participants returned
the self-administered questionnaire. As a consequence, describing the distribution of age at
first diagnosis seems more natural than describing the distribution of time elapsed between
baseline and diagnosis.
Figure 5.3 (panel A and B) exhibits the consequences of changing the time scale to the
survival experience of 10 random subjects from the COSM. In particular, in panel A the time
scale was follow-up time. Here, the beginning of the observation period coincided with the
time men were considered to become at risk (baseline, or 1 January 1998, or ‘time 0’). On the
other hand, in panel B the time scale for the same 10 individuals was changed to attained age,
which introduced delayed entries.
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Figure 5.3: Consequences of changing the primary time scale in a prospective cohort study from follow-
up time to attained age. Panels A and B illustrate the observation period for a subset of 10 participants
followed up until prostate cancer diagnosis (cross) or censoring (dot).
Consequences of delayed entries on the hazard and survival functions
The advantage of working with the hazard function is that it is not affected by delayed entries
— that is, by conditioning on survival until a given tentry. This is, of course, because the hazard
h(t) is already conditioned on being event-free at time t [equation (2.2)], and therefore it
makes no difference to additionally condition on survival until tentry < t. As a consequence,
the interpretation of the hazard function does not change.
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The survival function on the other hand, given its unconditional nature, is impacted
by the change in the time scale. Because of the presence of delayed entries, the survival
function is no longer estimating S(t), but rather S(t)/S(tmin) = S(t|tmin), where tmin =
min(tentry,1, . . . , tentry,n) is the earliest entry time (Lawless, 2003, section 3.5.1; Cleves et al.,
2010, section 8.2.3; Mackenzie, 2012). Despite this, the interpretation of the survival curve,
and in particular of the survival percentiles, remains difficult. In fact, it is no longer true that
the 100p-th survival percentile obtained from the survival curve — as illustrared in figure 2.7
— corresponds to the age by which 100p% of the study population has experienced the event
of interest.
For example, figure 5.4 shows the survival curves for prostate cancer incidence in the COSM
over the period 1998–2012 by county of enrollment, using age as the time scale. The survival
curves were obtained from a flexible hazard model using equation (2.9). Due to delayed entries
introduced by choosing attained age as the time scale, 65 years of age cannot be interpreted as
the age by which 5% of the men recruited in the Västmanland county developed prostate cancer.
As an extreme example of why this is so, think that less than 5% of the study participants from
Västmanland county might have in theory entered the COSM study by 65 years of attained
age.
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Figure 5.4: Survival curves for prostate cancer incidence in the COSM by county of enrollment, using
attained age as the time scale. Survival curves were obtained from a flexible hazard model with a
time-dependent coefficient for the enrollment county variable. Baseline hazard was modeled using RCS
with 5 knots. The red line refers to Västmanland county, while the blue line refers to Örebro county.
An intuitive way to circumvent this issue, and to obtain survival percentiles that are directly
interpretable, is to condition the survival curve on the unique entry times (baseline ages, in
our case). By doing so, the 100p-th survival percentile of age at the event can be interpreted
as the age by which 100p% of the subjects have experienced the event, conditional on a given
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baseline age.
Use of quantile regression to model and predict percentiles of attained age at the
event
Modeling and predicting survival percentiles of age at the event, conditionally on age at
baseline, is straightforward with quantile regression for censored data. This can be done
through the following model:
QAi (p|ageBaselinei) =  0(p) +
bX
r=1
 r(p)gr(ageBaselinei), (5.1)
where Ai is age at the event and ageBaselinei is the baseline age for the i-th individual — that
is, the individual’s entry time.
Age at baseline can be modeled using b flexible transformations, such as RCS or fractional
polynomials. Conversely, b = 1 and g1(·) equal to the identity function impose a linear re-
lationship between age at entry and the p-th percentile of age at the event. In this case, for
diseases whose occurrence increases with age (such as prostate cancer mortality), one would
generally expect to observe a positive regression coefficient  1(p).
Model 5.1 can be easily extended to include other covariates. For example, one could
include a binary variable ei in the model
QAi (p|ageBaselinei , ei) =  0(p) +
bX
r=1
 r(p)gr(ageBaselinei) +  b+1(p)ei . (5.2)
In this case, for a given p,  b+1(p) expresses the difference in the 100p-th percentile of
age at the event between exposed (ei = 1) and unexposed (ei = 0), conditional on age at
baseline. For example, if p = 0.5, the coefficient  b+1(0.5) estimates the differences in median
age at the event, conditional on baseline age. An implicit assumption of Model 5.2 is that the
association between the covariate e and the 100p-th percentile of age at the event is constant
across levels of age at baseline. This assumption can be relaxed by including in the model the
necessary product terms between gr(ageBaselinei) and ei .
For example, let ei take value 1 for those men enrolled in Västmanland county and value 0
for those enrolled in Örebro county. Based on Model 5.2, the predicted 5th and 10th percentiles
of age at prostate cancer diagnosis were, for 65-year-old men residing in Örebro county, equal
to 71 and 76 years, respectively. The between-county difference in the 5th percentile of age at
prostate cancer diagnosis was  6 months, while the 10th PD was  10 months, conditional on
baseline age. A richer picture of the association between county of enrollment and percentiles
of age at diagnosis is shown in figure 5.5.
More generally, the quantile regression model can be written as
QAi (p|ageBaselinei ,xi) =  0(p) +
bX
r=1
 r(p)gr(ageBaselinei) +
kX
j=1
 b+ j(p)xi j . (5.3)
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The considerations made for model (2.10) apply to model (5.3) as well. In particular,
the interpretation of the coefficients is appealing, as they are interpreted as differences in
percentiles of attained age at the time of the event.
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Figure 5.5: First 20 percentile differences (expressed in months) of age at prostate cancer diagnosis
between men enrolled in Västmanland county and men enrolled in Örebro county, conditional on
baseline age. The solid line is the point estimate, while dashed lines are 95% confidence intervals.
5.2.2 Body mass index and attained age at prostate cancer death
To illustrate the use of quantile regression to model percentiles of attained age at the event,
we will briefly re-analyze the updated data presented in section 5.1.2. The aim is to evaluate
the association between BMI and age at prostate cancer death.
As reported in section 5.1.2, BMI at baseline was modeled using RCS with 4 knots. Laplace
regression was used to model the 5th percentile of age at death adjusting for total energy intake
(kcal), total physical activity (MET-h/day), education (years), smoking status (current, former,
never smoker), family history of prostate cancer (yes, no, don’t know), personal history of
diabetes (yes, no), county of enrollment (Västmanland, Örebro), BMI at age 30 years (kg⇥m 2),
and age at baseline (years).
For every 5-unit increment in BMI the 5th percentile of age at prostate cancer death de-
creased by 4 months, although the 95% CI was observed to be quite wide ( 13 to 5 months).
No evidence of a non-linear association was observed (pnon-linearity = 0.41). Although the
magnitude of the 5th percentile difference (4 months) is not comparable with the magnitude
of the MRR estimated form the Cox PH model, the directions of the associations are consis-
tent. In particular, the negative coefficient from Laplace regression and the positive coefficient
from Cox regression model (log–mortality rate ratio) indicate a worse survival, when it comes
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to prostate cancer mortality, among overweight and obese men as compared with lean and
normal-weight men.
Figure 5.6 shows the dose–response association between BMI at baseline and differences
in the 5th percentile of age at prostate cancer death.
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Figure 5.6: Multivariable-adjusted differences in the 5th percentile of age at prostate cancer death by
levels of BMI at baseline. BMI was modeled using RCS with 4 knots (blue line), and in a linear fashion
(red line). The referent value was set at 22 kg⇥m 2. Black dashed lines represent the 95% confidence
interval for the linear model.
Results for the first 4 PDs in age at prostate cancer death were, for every 5-unit increment
in BMI,  2 (95% CI:  14 to 9),  3 (95% CI:  12 to 6),  3 (95% CI:  13 to 6), and  4 (95%
CI:  14 to 6) months.
5.3 Paper III
In this paper we reviewed the definition of RAP and its estimation, and critically discussed
certain misinterpretations appeared in the epidemiologic literature. Furthermore, we showed
how RAP estimation is sensitive to the specification of the age-disease association.
5.3.1 Misinterpretations of risk and rate advancement periods
We identified three major misinterpretations of RAP: first, equating RAP with the difference in
mean survival times; second, interpreting RAP as the time by which the survival curve for the
exposed individuals is shifted compared with that for the unexposed; third, equating the RAP
to a simple ratio of two logRRs.
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RAP as a di erence in mean survival time
The most common misinterpretation of RAP equates it with difference in mean survival time.
The two are, however, profoundly different quantities and using the former to estimate the
latter will inevitably lead to flawed conclusions.
Definition of RAP is given in equation (2.17) and is interpreted as the difference in base-
line age at which exposed individuals (e1) reach the same rate of the disease as unexposed
individuals (e0), under the assumption of a monotonic increase in event rate over age and
conditional on disease-free survival to some baseline age.
Mean survival time, on the other hand, equals the area under the survival curve (Mul-
downey et al., 2012). Consequently, difference in mean survival time between unexposed and
exposed individuals is defined as:
µe0  µe1 =
Z +1
0
S(t|e0)d t  
Z +1
0
S(t|e1)d t,
and is interpreted as the difference in the mean (expected) survival time between unexposed
and exposed subjects.
Table 5.2 reports synthetic data from an hypothetical cohort study with 10 exposed an 10
unexposed participants, including age at baseline in years, followed up for 36 months. Fitting
a Cox PH model to these data, with baseline age and exposure as covariates, resulted in an
estimated‘RAP= 1.594/0.109= 14.6 years, as per equation (2.20). Thus, under the model, we
would expect exposed subjects to experience the same disease rate as that among unexposed
subjects who were 14.6 years older at baseline.
To calculate difference in survival time for the same data, we estimated the two survival
curves from the PH model previously fitted, one for exposed and one for unexposed subjects,
fixing baseline age to the sample mean (57 years) [equation (2.6)]. The estimated difference
in mean survival between exposed and unexposed was equal to 9.2 months. Therefore, under
the model, we would expect the exposed subjects to live 9.2 months less as compared with
the unexposed subjects. This means that if one were to employ RAP to estimate mean–survival
difference, one would overestimate the latter by more than 13 years or, equivalently, over
19-fold.
There are other distinctions between RAP and difference in mean survival time that are
worth to be mentioned. First, the estimated RAP can be larger than the maximum follow-up
Table 5.2: Data from an hypothetical cohort study of 20 individuals (10 exposed and 10 unexposed)
followed up for 36 months
Unexposed Follow-up (months)a 6 6+ 7 11+ 16 16 19+ 22 23 36
Baseline age (years) 67 65 58 61 67 62 50 58 47 52
Exposed Follow-up (months)a 1 4+ 5 6 6+ 6 11 12+ 15 22
Baseline age (years) 61 67 58 49 52 56 50 49 51 57
a + indicates a censored observation.
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time, while the difference in mean survival must by definition be smaller than the largest
follow-up time. Second, mean survival can be estimated only if one observes the upper tail
of the survival distribution, which is often not the case due to censoring. This is true unless
one is willing to assume some parametric distribution for the p.d.f. of survival time T and
then extrapolate the survival curve beyond the observed follow-up period. Third, the unit of
measurement of RAP is only determined by that of baseline age, and has nothing to do with
the unit of measurement of follow-up time. This means that if in table 5.2 the follow-up times
were days instead of months, RAP would still be 14.6 years, but the difference in mean survival
time would become 9.2 days.
RAP as a shift of the survival curve
RAP has been interpreted as “by how many months or years the survival curve among the
exposed is ‘advanced’ or brought forward compared with the survival curve among the unex-
posed” (Brunekreef et al., 2007). However, under PH, RAP is the difference in baseline age for
which the survival curve for the unexposed individuals is equal to the survival curve for the
exposed individuals, given that all other covariates are kept constant. In other words, RAP is
the difference in baseline ages a0  a1 such that S(t|e0, a0,c) = S(t|e1, a1,c).
In fact, under PH, equation (2.6) holds and by taking the complementary log-log transfor-
mation of S(t|e, a,c), one obtains
log
⇥  log [S(t|e, a,c)]⇤= log⇥  log⇥S0(t)⇤⇤+  1e+  2g(a) + kX
i=1
 i+2ci ,
from which equation (2.19) immediately follows.
RAP can therefore be equally defined as the difference in baseline age by which a group of
e1-exposed subjects experiences the same survival as e0-exposed subjects, assuming a strictly
increasing disease rate over age and disease-free survival to baseline age.
RAP as a concept similar to relative risk
RRs measure the association between an exposure and the occurrence of a disease. Although
they may vary with age, they do not conceptually depend on age. RAP, on the other hand, are
not measures of association in the traditional sense, but rather they measure the exposure
dependence of a relation between age and disease. As Brenner et al. (1993) pointed out “given
a fixed magnitude of the exposure-disease association, risk or rate advancement periods are
inversely related to the age gradient of disease risk or rate”. In particular, even strong exposure-
disease associations can be dominated by the age effect, depending on the strength of the age
disease association, resulting in short advancement periods.
To illustrate this point, imagine two diseases, d1 and d2, whose rates h1(a, e) and h2(a, e)
are functions of a binary exposure e and age at baseline a (measured in years). In particular,
h1(a, e) = k14ea5 and h2(a, e) = k21.1ea1/5, where k1 and k2 are baseline rates, possibly
depending on follow-up time. The exposure-disease association is stronger for d1 (RR = 4)
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than for d2 (RR = 1.1), at any given baseline age. After logarithmic transformation of these
models, the RAP for d1 is found from
log
 
k1
 
+ 5 log
 
a0
 
= log
 
k1
 
+ log (4) + 5 log
 
a1
 
,
which gives (41/5 1)a1 = 0.32a1; similarly, RAP for d2 is (1.11/5 1)a1 = 0.61a1 [see equation
(2.21)]. Therefore, RAP is greater for d2 than for d1 at any baseline age, despite the RR being
higher for d1 than for d2.
This simple example shows the fact that strong associations — that is, large RRs — need
not lead to a large RAP, or vice versa. RAP thus provide a different perspective on RRs and
shows that even exposures that are strongly positively associated with the occurrence of the
disease may not turn out to be important from a public-health point of view, if what they do is
to shift a very steep age-incidence curve by a short time period.
5.3.2 Misspecification of the age-disease association
Estimation of RAP is particularly sensitive to the form of the age-disease dependence g(a) in
the rate or risk model. This means that if the true association between the occurrence of the
disease and baseline age is non-linear, including age in the model as a linear term (g(a) = a)
can severely bias the RAP estimates.
Suppose for example that the risk r of a disease d follows the logistic model
logit(r) =  10+ log (2) e+ 2 log (a) . (5.4)
From equation (2.21), RAP at baseline age a1 is equal to 0.414a1, so that, between baseline
ages of, say, 45 and 80 years, RAP increases from 11.7 to 20.8 years.
To assess the bias deriving from misspecifying the functional form of age, we carried out
a simulation from a population in which exposure e followed a Bernoulli(0.5) distribution,
baseline age a followed a Uniform(45,80) distribution (independent of e), and d was randomly
generated from the logistic model (5.4). Taking 2,000 samples of size 500 each, we estimated
RAP from the misspecified logistic model logit(r) =  0 +  1e +  2a. The mean and median
simulated RAP estimates were 25.4 and 21.5 years, constant over baseline age, not even in the
correct range — that is, between 11.7 and 20.8 years. Figure 5.7 shows the distribution of the
2,000 RAP estimates from the misspecified model.
5.3.3 Body mass index and prostate cancer mortality rate advancement period
Using the updated COSM data presented in section 5.1.2, we observed no evidence of non-
linearity between baseline age and prostate cancer MR (pnon-linearity = 0.18) and, at the same
time, the assumption of monotonicity in the age-disease association seemed to hold (data not
shown).
Based on equation (2.20), the RAP comparing obese men at baseline (  30 kg⇥m 2)
with normal-weight men (21.0–22.9 kg⇥m 2) was equal to 18 months. Therefore, under the
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Figure 5.7: Distribution of 2,000 RAP estimates from the misspecified logistic model in the simulation
study. The dashed vertical line indicates the mean of the distribution (25.4 years), while the solid
vertical line indicates the median (21.5 years).
model, one would expect obese men to experience the same prostate cancer MR as that among
normal-weight men who were 18 months older at baseline. The RAP for every 5-unit increment
in BMI was equal to 8 months.
Even if there was not enough evidence to reject the linearity assumption in the age-disease
relation, the sensitivity of the previous estimates was examined by modeling age with a natural
logarithm transform [equation (2.21) for RAP applies]. The RAP comparing obese men (  30
kg⇥m 2) with normal-weight men (21.0–22.9 kg⇥m 2) was equal to 11 months for men aged
45 years old at baseline and 17 months for men aged 70 years old. The RAP for every 5-unit
increment in BMI increased linearly from 5 to 7 months for men aged 45 and 70 years old,
respectively. This, again, illustrates the high sensitivity of RAP to the form of the age-disease
dependence.
5.4 Paper IV
Aim of this paper was to summarize the existing epidemiologic evidence — available as aggre-
gated data — on the dose–response association between BMI and the incidence of localized
and aggressive prostate cancer. Furthermore, possible differences in the dose–response asso-
ciation according to study-level covariates were investigated. Only prospective studies were
included in this meta-analysis.
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5.4.1 Main results
Random-e ect dose–response meta-analysis
For localized prostate cancer, we observed a 6% decreased incidence for every 5-unit increment
in BMI [RR: 0.94 (95% CI: 0.91–0.97)]. No evidence of a non-linear relationship was found
when BMI was modeled using a quadratic polynomial (pnon-linearity = 0.10). In the linear model,
there was no evidence of heterogeneity (pheterogeneity = 0.27, I2 = 18%) or publication bias
(ppublication bias = 0.35 from the Egger’s test).
For advanced prostate cancer, we found a 9% increased incidence for every 5-unit increment
in BMI [RR: 1.09 (95% CI: 1.02–1.16)]. Again, no evidence of non-linearity was observed
(pnon-linearity = 0.10). There was, however, a moderate amount of between-study heterogeneity
(pheterogeneity = 0.08, I2 = 38%) and evidence of publication bias (ppublication bias = 0.02). A
large part of the observed heterogeneity was due to one single study conducted in Australia,
that reported a RR of 1.51 (95% CI: 1.14–2.01) (MacInnis et al., 2003). Removing this study
led to a decrease in the between-study variability (pheterogeneity = 0.26, I2 = 18%), while the
pooled RR for every 5-unit increment in BMI changed only marginally [RR: 1.07 (95% CI:
1.01–1.13)].
Meta-regression and sensitivity analysis
By means of meta-regression, we assessed whether the dose–response associations differed
according to the following study-level characteristics: method of BMI collection (trained per-
sonnel versus self-reported measurements), and degree of adjustment (adjustment for physical
activity and personal history of diabetes versus adjustment for only one or neither of these
covariates). However, we did not observe evidence of effect modification by these study-level
covariates, neither for localized nor for advanced prostate cancer.
Since the dose–response meta-analysis could have been sensitive to the choice of the BMI
level assigned to the open-ended categories (Crippa et al., 2015), we carried out a sensitivity
analysis assuming that the amplitude of the open-ended categories was twice that of the
neighborhood categories. In this scenario, the RRs for every 5-unit increment in BMI were
observed to be 0.95 (95% CI: 0.93–0.98) and 1.07 (95% CI: 1.01–1.13) for localized and
advanced prostate cancer, respectively.
Lastly, we performed a series of sensitivity analyses regarding the classification criteria
used in some of the studies. First, in the meta-analysis on localized prostate cancer, we pooled
the results for ‘moderate grade’ (Gleason score 5–7) with those for ‘low grade’ prostate cancer
(Gleason score 2–4) in the study by MacInnis et al. (2003). Second, in the meta-analysis on
advanced prostate cancer, we pooled the results for ‘non-metastatic high grade’ with those for
‘stage D or fatal’ cases in the study by Rodriguez et al. (2007). Third, we used the classification
criterion based on Gleason score instead of the that based on the TNM staging system in
the study by Pischon et al. (2008). Fourth, we excluded from the meta-analysis on localized
prostate cancer those three studies that used Gleason score as the only criterion to classify
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incident cases (Cerhan et al., 1997; MacInnis et al., 2003; Putnam et al., 2000). The pooled
RRs did not appreciably change in any of these sensitivity analyses.
5.4.2 Updated dose–response meta-analysis
Localized prostate cancer
Figure 5.8 shows the 14 study-specific dose–response associations, where BMI was modeled
using RCS with 3 knots positioned at the 10th, 50th, and 90th percentiles of the BMI distribu-
tion23 (blue line) and in a linear fashion (red line). The regression model for the i-th study
was
E
Ä
yi j
ä
=  i1
î
g1
Ä
xi j; 
ä  g1  xi0;  ó+  i2 îg2 Äxi j; ä  g2  xi0;  ó ,
for i = 1, . . . , 14 and j = 1, . . . , Ji . The functions g1(·) and g2(·)were the 2 RCS transformations
characterized by the vector   containing the knots position.
The 14 vectors of study-specific regression coefficients   i were then pooled using the
random-effect bivariate meta-analysis model 
 i1
 i2
!
⇠ N2
  
✓1
✓2
!
,
24Vˆ( i11) Vˆ( i12)
Vˆ( i21) Vˆ( i22)
35+24 11  12
 21  22
35! ,
whose parameters were estimated by REML.
Overall, BMI was associated with the incidence of localized prostate cancer in the RCS
model (poverall < 0.001) and evidence of non-linearity was observed (pnon-linearity < 0.001),
as illustrated in figure 5.9 (blue line). Compared with a BMI of 22 kg⇥m 2, the pooled RRs
were 1.01 (95% CI: 0.99–1.04) for 25 kg⇥m 2, 0.93 (95% CI: 0.90–0.98) for 30 kg⇥m 2,
and 0.81 (95% CI: 0.74–0.88) for 35 kg⇥m 2. Between-study heterogeneity was marginal
(pheterogeneity = 0.28, I2 = 12%), as measured by the multivariable extensions of the Q test and
of the I2 statistic [equations (2.28) and (2.29)]. BMI was also modeled using RCS with knots
placed at the 25th, 50th, and 75th percentiles of the BMI distribution24 (purple line) and a
quadratic polynomial (green line), as in Paper IV. These 2 alternative exposure transforma-
tions gave very similar results as compared with the main analysis, both in terms of predicted
population-average dose–response associations and between-study heterogeneity. Lastly, ex-
cluding the study by Gong et al. (2006), which did not report enough data to approximate the
covariance between the logRR estimates, did not virtually change the pooled dose–response as-
sociation, while the between-study heterogeneity decreased to I2 = 3% (pheterogeneity = 0.42).
Advanced prostate cancer
Similarly to what described before, figure A.4 exhibits the 18 study-specific dose–response
associations between BMI and incidence of advanced prostate cancer. BMI was modeled using
23Corresponding to 22.0, 26.1, and 32.5 kg⇥m 2.
24Corresponding to 22.8, 26.1, and 28.8 kg⇥m 2.
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Figure 5.8: Study-specific dose–response associations between BMI and incidence of localized prostate
cancer in the updated meta-analysis including 14 prospective studies. BMI was modeled using RCS
with 3 knots positioned at the 10th, 50th, and 90th percentiles of the overall BMI distribution (blue
line) and in a linear fashion (red line). Dashed black lines represent the 95% CI for the RCS models.
The vertical axes are on the natural log scale. Figure continued on next page.
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Figure 5.9: Pooled dose–response association between BMI and incidence of localized prostate cancer
from a random-effect multivariate meta-analysis. BMI was modeled using RCS with 3 knots positioned
at the 10th, 50th, and 90th percentiles of the BMI distribution (blue line), with RCS with 3 knots
positioned at the 25th, 50th, and 75th percentiles of the BMI distribution (purple line), and with a
quadratic polynomial transformation (green line). Dashed black lines represent the 95% CI for the first
RCS model. BMI equal to 22 kg⇥m 2 served as the referent group. The vertical axis is on the natural
log scale.
RCS with 3 knots positioned at the 10th, 50th, and 90th percentiles of the BMI distribution25
(blue line) and in a linear fashion (red line). The 18 vectors of study-specific regression
coefficients used as the outcome in a random-effect bivariate meta-analysis model.
Although BMI was associated with the incidence of advanced prostate cancer in the mul-
tivariate model pooling the study-specific RCS regression coefficients (poverall = 0.004), no
evidence of non-linearity was observed (pnon-linearity < 0.89) (figure 5.10, blue line). For this
reason, study-specific regression coefficients where BMI was modeled in a linear fashion were
pooled by means of a univariate random-effect meta-analysis. For every 5-unit increment in
BMI, the incidence of advanced prostate cancer was observed to increase by 7% [RR: 1.07
(95% CI: 1.03–1.12)] (red line). Between-study variability was limited as compared to total
variability (pheterogeneity = 0.15, I2 = 26%). Removing those two studies that did not report
information about number of cases and person-years by categories of BMI did not appreciably
change the results [RR: 1.08 (95% CI: 1.03–1.13) for every 5-unit increment, I2 = 27%]
(Habel et al., 2000; Gong et al., 2006). A forest plot reporting the 18 study-specific RRs for
every 5-unit increment in BMI is shown in figure A.5.
25Corresponding to 22.0, 26.0, and 31.6 kg⇥m 2.
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Figure 5.10: Pooled dose–response association between BMI and incidence of advanced prostate cancer
from a random-effect multivariate meta-analysis. BMI was modeled using RCS with 3 knots positioned
at the 10th, 50th, and 90th percentiles of the BMI distribution (blue line), and in a linear fashion (red
line). Dashed black lines represent the 95% CI for the linear model. BMI equal to 22 kg⇥m 2 served as
the referent group. The vertical axis is on the natural log scale.
5.5 Paper V
The aim of Paper V was to present, discuss, and practically illustrate 3 tools that can help
to evaluate the goodness of fit of a dose–response meta-analysis: deviance, coefficient of
determination (R2), and decorrelated-residuals–versus–exposure plot.
These tools were presented in Paper V using the notation following the ‘one-stage’ or ‘pool-
first’ dose–response meta-analytic approach. However, they can be equivalently expressed in
terms of notation based on the two-stage approach. In the next sections, we will follow this
alternative way of presenting the 3 tools. Note that in the following exposition it is assumed
that ⌃i = V(  i) and that the assigned dose xi0 for the referent level of the exposure is equal
to 0 for all the studies.
5.5.1 Goodness of fit tools for dose–response meta-analysis
Deviance
In dose–response meta-analysis, the data points to be fitted are the non-referent logRRs re-
ported by the single studies. Therefore, analysis of residuals can be useful to evaluate how
close reported and predicted logRRs are at each exposure level. Study-specific vectors of resid-
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uals, calculated as the difference between the observed logRRs and the model predictions from
the overall dose–response function, are equal to
ei = yi  XiZi ✓ˆ .
A statistic for the absolute goodness of fit based on these residuals is the deviance statistic,
which is defined as
D =
KX
i=1
Di =
KX
i=1
Ä
yi  XiZi ✓ˆ
ä>
S 1i
Ä
yi  XiZi ✓ˆ
ä
=
KX
i=1
e>i S 1i ei . (5.5)
The deviance measures the total absolute distance between reported and fitted logRRs
while taking into account the correlation structure of the study-specific logRRs through the
matrices Si — that is, the generalized residual sum of squares (GRSS). Intuitively, the smaller
the deviation, the closer the reported and predicted logRRs will be.
Building on the assumption that the single logRRs are normally distributed, the deviance
provides a test for model specification. Under the null hypothesis that the model is correctly
specified, D is asymptotically distributed as a chi-square random variable with n  qm degrees
of freedom (df), where n=
PK
i=1 Ji . This means that testing for model specification amounts to
testing whether, under the null hypothesis, the residual variance corrected for the correlation
between the logRRs is larger than one would expect. A small p-value indicates that there
is evidence that the posited model fails in accounting for the observed variation among the
logRRs.
Coe cient of determination
A descriptive statistic that can be used as a complement to the deviance to summarize the
goodness of fit of a given model is the coefficient of determination (R2). This statistic evaluates
the agreement between observed and predicted logRRs and, unlike the deviance, is bounded
between 0 and 1 (Hagquist and Stenbeck, 1998; Kvålseth, 1985).
Given that the generalized total sum of squares (GTSS) is equal to
PK
i=1 y
>
i S
 1
i yi , and given
the lack of the intercept term, R2 is defined, following the work of Theil (1961, section 6.2)
and Buse (1973), as:
R2 = 1  GRSS
GTSS
= 1 
KP
i=1
Ä
yi  XiZi ✓ˆ
ä>
S 1i
Ä
yi  XiZi ✓ˆ
ä
KP
i=1
y>i S 1i yi
.
R2 is a dimensionless index that measures the proportion of the GTSS accounted for by the
exposure and study-level covariates. It takes value 0 if the dose–response meta-analytic model
explains no variability in the observed logRRs, while it takes value 1 if the model accounts for
all the observed variability among the logRRs. Generally, a low R2 might be an indication that
66 5. Results
a more flexible transformation of the exposure and/or a meta-regression model is needed.
An adjusted version of R2 that is penalized by the number of total covariates included in
the first and second stage of the dose–response meta-analysis is given by
R2adj = 1  nn  qm
Ä
1  R2ä .
R2adj increases only if the increment in R
2 is larger than what would be expected by chance
alone and can prove useful to compare the fit of non-nested models.
Visual assessment
Visual inspection of the model fit can reveal important data features and model shortcomings
that may otherwise go undetected (Kvålseth, 1985). Visual assessment of the goodness of
fit in dose–response meta-analysis is however made more difficult due to the fact that the
study-specific logRRs are correlated. As a consequence, the fitted dose–response curve might
not even pass through the data points, depending on the particular correlation structure of the
residuals, and a simple plot overlaying the dose–response curve to the reported logRRs might
therefore be highly misleading. This issue is illustrated in figure 5.11 using the aggregated
data reported in table 2.4. This is the reason why, for example, in figure 5.8 we decided to not
overlay the observed RRs to the study-specific regression curves. To avoid this problem, one
can plot the decorrelated residuals versus the exposure.
The decorrelated residuals are obtained by decomposing each study-specific matrix Si
through Cholesky factorization, so that Si = CiC>i , where Ci is a lower triangular matrix.26
The study-specific decorrelated residuals e⇤i are then obtained by multiplying the inverse of Ci
by the difference between reported and fitted logRRs:
e⇤i = C 1i
Ä
yi  XiZi ✓ˆ
ä
= C 1i ei .
Lastly, the decorrelated residuals for all the studies are plotted against the exposure.
Although the vertical distances from the reference line drawn at e⇤ = 0 have no meaningful
interpretation, it is still possible to assess how the pooled dose–response curve fits the data
according to exposure levels. If the fit is perfect, all the points will lie on the reference line. As
the fit gets worse, the points will move away from it. A pattern in the decorrelated residuals
might indicate for example that the fit of the model is adequate only at certain exposure levels
or that study-level covariates need to be taken into account, therefore suggesting the need
of a richer dose–response model. Overlaying a LOWESS smoother to the plot or changing
the shape/color of the points according to study-level covariates might help to detect such
patterns.
26Equivalently, S 1i = (C 1i )>(C 1i ).
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Figure 5.11: Fitted linear trend (solid line) based on IRRs (hollow circles) and exposure values reported
in a single study (table 2.4). Due to the correlation among the IRRs, the linear trend does not pass
through the data points. The vertical axis is on the natural log scale.
Goodness of fit of study-specific dose–response models
The three tools presented so far can be also used to assess the goodness of fit of the first-
stage study-specific dose–response models, if one wishes so. Only minor modifications in the
formulae are necessary. In particular, it is sufficient to replace the pooled parameter vector ✓ˆ
with the study-specific parameter vectors  ˆ i and drop the second-stage design matrix Zi .
Let the study-specific decorrelated residuals be
e˜⇤i = C 1i
Ä
yi  Xi ˆ i
ä
= C 1i e˜i .
These residuals can be used to construct study-specific decorrelated-residuals–versus–exposure
plots.
The deviance for the i-th study-specific dose–response regression model is defined as
D˜i =
Ä
yi  Xi ˆ i
ä>
S 1i
Ä
yi  Xi ˆ i
ä
= e˜>i S 1i e˜i ,
and when the i-th study-specific model is correctly specified, D˜i asymptotically follows a chi-
square random variable with Ji q degrees of freedom. Moreover, as the K studies are summed
to be independent, it is also possible to set up a joint test for model specification of all the K
first-stage study-specific dose–response regressions. In fact, under the null hypothesis that all
the first-stage models are correctly specified, the sum of the K study-specific deviances D˜i is
asymptotically distributed as a chi-square random variable with
PK
i=1(Ji q) = n Kq degrees
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of freedom:
D˜ =
KX
i=1
D˜i =
KX
i=1
e˜>i S 1i e˜i ⇠  2n Kq. (5.6)
Lastly, the coefficient of determination for the i-th study is defined as
R2i = 1 
Ä
yi  Xi ˆ i
ä>
S 1i
Ä
yi  Xi ˆ i
ä
y>i S 1i yi
.
Relation between D and Q statistics
Analogously to the vector of decorrelated residuals e⇤i , let the following objects
y⇤i = C 1i yi
X⇤i = C 1i Xi ,
be the vector of decorrelated non-referent logRRs and the decorrelated design matrix for the
i-th study. Suppose also for sake of simplicity that Zi = I(Ji) for i = 1, . . . ,K .
It is possible to show that the difference between D [equation (5.5)] and Q [equation
(2.28)] is equal to D˜ [equation (5.6)]. In fact,
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The difference between D and Q is therefore
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A direct consequence of this relation is that D   Q. In particular, D = Q when all the
first-stage study-specific regression models fit perfectly the reported logRRs — that is, R2i = 1
for every i.
Perhaps not surprisingly at this point, the degrees of freedom of D minus the degrees of
freedom of Q is equal to the degrees of freedom of D˜. In fact
n  qm  (Kq  qm) = n  Kq.
5.5.2 Goodness of fit assessment: dose–response meta-analysis on body mass
index and incidence of localized prostate cancer
To illustrate the 3 tools introduced in the previous section, we will evaluate the goodness of fit
of the updated dose–response meta-analysis on BMI and incidence of localized prostate cancer
presented in section 5.4.2. This meta-analysis was based on 18 prospective studies for a total
of 46 non-referent logRRs.
The identity transformation for BMI — that is, modeling BMI linearly — resulted in a
particularly poor goodness of fit (model 1). In particular, the test for model specification
70 5. Results
showed evidence of lack of fit, as indicated by a deviance of 64 on 46  1 = 45 degrees of
freedom (p = 0.03) (table 5.3). The percentage of total variability in the non-referent logRR
estimates explained by this model was R2 = 29%. Furthermore, the decorrelated-residuals–
versus–exposure plot showed that the fit of the model was poor. In particular, the decorrelated
residuals were mostly positive for low values of the rescaled exposure, while they were almost
all negative for high exposure values (figure 5.12, panel A).
The lack of fit of model 1 was addressed by modeling BMI using RCS with 3 knots po-
sitioned at the 10th, 50th, and 90th percentiles of the exposure distribution (model 2). The
improvement in the goodness of fit of model 2 over model 1 was reflected by the increase in
the coefficient of determination (from 29% to 48%) and by the large reduction in the deviance
with respect to the difference in the degrees of freedom (D = 64  47= 17, df= 45  44= 1,
pnon-linearity < 0.001) (table 5.3). Furthermore, the decorrelated-residuals–versus–exposure
plot reflected the improved fit of model 2, especially for the right tail of the exposure distri-
bution (figure 5.12, panel B). Lastly, from the test for model specification, we observed no
evidence of lack of fit for model 2 (D = 47, df= 46  2= 44, p = 0.35).
Similar conclusions regarding the goodness of fit of the pooled dose–response curve fol-
lowing a non-linear transformation of the exposure were reached when using the other two
transformations proposed in section 5.4.2, namely RCS with 3 knots positioned at the 25th,
50th, and 75th percentiles (model 3), and quadratic polynomial (model 4). A summary of the
goodness of fit for the 4 models considered here is reported in table 5.3.
Table 5.3: Goodness of fit measures for the updated dose–response meta-analysis on BMI and incidence
of localized prostate cancer presented in section 5.4.2
Model BMI transformation Deviance df p-valuea p-valueb R2 R2adj
1 Linear (identity) 64 45 0.03 — 29% 29%
2 RCS with 3 knotsc 47 44 0.35 < 0.001 48% 45%
3 RCS with 3 knotsd 44 44 0.45 < 0.001 50% 48%
4 Quadratic polynomial 49 44 0.26 < 0.001 45% 42%
a p-value from the test for model specification.
b p-value for relative goodness of fit with respect to model 1.
c Knots positioned at the 10th, 50th, and 90th percentiles of BMI distribution.
d Knots positioned at the 25th, 50th, and 75th percentiles of BMI distribution.
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Figure 5.12: Decorrelated residuals (hollow circles) and LOWESS smoother (black line) for model 1
(panel A) and for model 2 (panel B) in the updated dose–response meta-analysis on BMI and incidence
of localized prostate cancer presented in section 5.4.2.
Chapter 6
Discussion
6.1 Body mass index and prostate cancer incidence and mor-
tality
6.1.1 Major findings and comparison with literature results
BMI during middle-late adulthood
In Paper I and Paper IV we observed a dual association between BMI during middle-late
adulthood an prostate cancer: an increased risk of advanced and fatal prostate cancer, and a
decreased risk of localized prostate cancer (comparing overweight and obese men to normal-
weight men). These findings support the hypothesis of etiological heterogeneity of prostate
cancer in relation to obesity (Discacciati and Wolk, 2014).
In Paper I we observed an inverse–U shaped relation between BMI and incidence of lo-
calized prostate cancer. This result was also observed in the updated analyses with a longer
follow-up period and, noteworthy, it was robust to different modeling strategies of the exposure.
Although no evidence of non-linearity was observed in Paper IV, the updated meta-analysis
showed a similar dose–response relation to that reported in Paper I. Furthermore, the effect
size estimates were remarkably similar. A lower localized prostate cancer incidence was ob-
served in particular for overweight and obese men as compared with normal-weight men. The
decreased incidence for underweight men was much less pronounced.
An increased incidence of advanced prostate cancer was observed both in Paper I and in
Paper IV. Results were again consistent, especially considering the updated analyses carried
out in this thesis, where a 7–11% increased IR was observed for every 5-unit increment in BMI.
Consistently with the results for advanced prostate cancer, a 12% increased MR was ob-
served for death due to prostate cancer in Paper I. The increased number of cases due to
the extended follow-up time contributed in making the estimated MRR slightly more precise.
In addition, the worse survival associated with increased BMI levels was also observed when
analyzing the percentiles of age at prostate cancer death using quantile regression for censored
data.
These results are in line with recent epidemiologic literature. Higher BMI levels were
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observed to be associated with lower localized prostate cancer incidence in a large dose–
response meta-analysis, where a non-linear relation was observed (WCRF and AICR, 2014).
Interestingly, an inverse–U shaped association between BMI and the incidence of total prostate
cancer was also found in a very large population-based cohort study of 5.24 million adults in
the United Kingdom (Bhaskaran et al., 2014). Although the analyses were not carried out by
specific subtypes of prostate cancer, one might speculate that the presumably high proportion
of localized cases conferred to the association an inverse–U shape.
BMI was positively linearly associated with advanced prostate cancer in many, but not all,
of the cohort studies that we included in the meta-analysis, as shown in figure A.4. However,
the results from a recent dose–response meta-analysis of 24 cohort studies are in agreement
with our findings (WCRF and AICR, 2014). Comparable results were also observed in a “high
versus low” meta-analysis (Zhang et al., 2015).
Lastly, a positive association between BMI and prostate cancer mortality, similar in magni-
tude to what we observed in the COSM, was reported in a dose–response meta-analysis of 6
population-based cohort studies [RR for every 5-unit increment in BMI: 1.15 (95% CI: 1.06–
1.25)](Cao and Ma, 2011). A large study, not included in the aforementioned meta-analysis,
also observed a positive association between BMI and prostate cancer MR (Häggström et al.,
2012). Consistently with these findings, BMI was observed to be associated with a higher IR of
biochemical recurrence (Bassett et al., 2005; Strom et al., 2005, 2006; Efstathiou et al., 2007b;
Palma et al., 2007; Ly et al., 2010; Cao and Ma, 2011) and with a higher rate of prostate
cancer–specific mortality in many (Efstathiou et al., 2007a; Gong et al., 2007; Ma et al., 2008;
Cao and Ma, 2011; Cantarutti et al., 2015), but not all studies (Bonn et al., 2014).
BMI during early adulthood
In Paper I, no evidence of an association between BMI during early adulthood and incidence
of localized prostate cancer was observed. This lack of evidence remained also after extending
the follow-up until 31 December 2011. Although we observed inverse associations between
BMI at age 30 years and the risk of advanced and fatal prostate cancer, these results were very
weak.
Comparison of these results with other studies is complicated due to the heterogeneity in
the time window considered for the exposure (Robinson et al., 2008; Sutcliffe and Colditz,
2013). A systematic review and dose–response meta-analysis of 16 studies on BMI measured
at 18–29 years of age and total prostate cancer observed a 6% increased risk for every 5-unit
increment in early-adult BMI [RR: 1.06 (95% CI: 0.99–1.14)] (Robinson et al., 2008). In
particular, the pooled RR for the 5 studies reporting BMI during the ages 25–29 years was
equal to 1.14 (95% CI: 1.00–1.30), in contrast with our findings. Studies analyzing BMI ‘during
college’ age and ‘during the twenties’ reported weaker associations.
Only a few studies investigated the association between BMI during early adulthood by
subtype of the disease. For localized prostate cancer, findings were inconsistent (Schuurman
et al., 2000; Littman et al., 2007; Wright et al., 2007). Similarly, results for advanced prostate
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cancer were heterogeneous, ranging from inverse (Möller et al., 2015) to direct associations
(Schuurman et al., 2000; Dal Maso et al., 2004). However, the majority of the studies reported
very little evidence of an association (Giles et al., 2003; Robinson et al., 2005; Littman et al.,
2007; Wright et al., 2007; Möller et al., 2013). Not surprisingly, these inconsistent results were
also observed for prostate cancer mortality (Wright et al., 2007; Burton et al., 2010; Möller
et al., 2013, 2015).
6.1.2 Biological mechanisms
BMI during middle-late adulthood
Possible biological mechanisms that could explain the associations between BMI and prostate
cancer incidence and mortality observed in Paper I and Paper IV are still partially unclear.
However, three pathways in particular have been proposed in the literature: the insulin/insulin-
like growth factor 1 (IGF-1), the sex hormones, and the inflammation pathway (Wirén and
Stattin, 2008; Roberts et al., 2010; Renehan et al., 2015).
First, obesity is associated with hyperinsulinemia which in turn, due to decreased levels of
IGF-binding proteins 1 and 2, increases the circulating amounts of bioactive IGF-1 (Nam et al.,
1997), a growth factor with a pathogenic role in many cancers (Roberts et al., 2010). High
levels of IGF-1, in particular, have been associated with increased prostate cancer incidence in
2 meta-analyses (Renehan et al., 2004; Rowlands et al., 2009) and in a large pooling project
of 12 prospective studies (Roddam et al., 2008). However, a shortcoming of this explanation
is that mean IGF-1 levels have been observed to be non-linearly associated with BMI, peaking
at 24–26 kg⇥m 2 (Yamamoto and Kato, 1993; Lukanova et al., 2002). Interestingly, this was
roughly the BMI range where the highest incidence of localized prostate cancer was observed
in Paper I (figure 5.2) and in the updated dose–response meta-analysis (figure 5.9).
Second, obesity is linked with decreased androgen levels (Lima et al., 2000). No evidence
of an association between androgens and incidence of total prostate cancer was observed in
a large collaborative analysis of 18 prospective studies (Endogenous Hormones and Prostate
Cancer Collaborative Group et al., 2008). At the same time, in line with our findings, lower
concentrations of free testosterone were observed to be linked with a decreased incidence of
non-aggressive well-differentiated prostate cancer and with an increased incidence of aggres-
sive low-differentiated prostate cancer in two prospective cohort studies (Platz et al., 2005;
Severi et al., 2006). Furthermore, it has been observed that, among men diagnosed with
prostate cancer, those with lower testosterone levels have a higher prevalence of the aggres-
sive phenotype (Hoffman et al., 2000; Schatzl et al., 2001; D’Amico et al., 2002; Massengill
et al., 2003; Schnoeller et al., 2013). It has been therefore speculated that low testosterone
levels may promote the development of aggressive prostate cancer (Hsing et al., 2007; Freed-
land and Platz, 2007). Lastly, in the PCPT it was observed that finasteride, a drug that lowers
dihydrotestosterone levels, decreased overall prostate cancer risk, but at the same time it in-
creased the risk of high-grade tumors (Gleason score 7–10) (Thompson et al., 2003). In the
long-term analyses with 18 years of follow-up, finasteride was again observed to reduce the
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risk of prostate cancer (Thompson et al., 2013). This reduction was entirely due to fewer low-
grade tumors (Gleason score 2–6), as high-grade prostate cancers were still more common in
the finasteride arm. The relative increase of high-grade tumors, however, decreased from 27%
in the primary study to 17% in the long-term study.
Third, obesity is a state of chronic inflammation mediated through altered levels of adipokines,
such as leptin (a potent inflammatory agent) or adiponectin (an anti-inflammatory adipokine).
Leptin, which is elevate in obesity, has been observed to have a pro-tumor potential in vitro
(Somasundar et al., 2004), but epidemiologic studies observed no evidence of an association
with prostate cancer risk or tumor stage at prostatectomy (Freedland et al., 2005; Baillargeon
et al., 2006; Li et al., 2010). Conversely, adiponectin has anti-tumor properties and its serum
levels are decreased in obese individuals (Freedland et al., 2010; Dalamaga et al., 2012).
Adiponectin has been found to be inversely associated with metastatic prostate cancer inci-
dence and mortality (Li et al., 2010). Moreover, adiponectin levels have been observed to be
inversely associated with tumor’s histologic grade and disease stage among men diagnosed
with prostate cancer (Goktas et al., 2005).
BMI during early adulthood
The physiologic changes during the developmental stages of the prostate and immediately
thereafter — when the prostate may be more susceptible to endogenous and exogenous car-
cinogenic exposures —may play an important role in tumor initiation and development (Hsing,
1996; Giovannucci et al., 1997; Sutcliffe and Colditz, 2013). However, the biologic mechanisms
that may explain a possible link between prostate cancer risk and obesity during childhood,
puberty and early adulthood are unclear.
Adiposity during early life and adolescence, which has been observed to often persist
during adulthood (The et al., 2010), has been found to be associated with delayed pubertal
development in boys (Wang, 2002). Due to the fact that puberty is associated with a steep
increase in IGF-1 levels (Keenan et al., 1993; Juul et al., 1994), a delayed pubertal development
could, in theory, lead to a lower cumulative exposure to IGF-1 and/or a lower exposure during
those ages that are crucial for prostate development. In addition, obesity during earlier stages
of life is linked with later diabetes incidence, which in turns has been consistently observed to
be inversely associated with the risk of prostate cancer (Jian Gang et al., 2015).
These speculative biological mechanisms could partially explain the inverse association
that we observed between BMI at age 30 years and incidence of advanced prostate cancer and
prostate cancer mortality.
6.1.3 Detection bias
There is a number of factors that could make prostate cancer detection more difficult in obese
men. This relationship between body adiposity and detection sensitivity could lead to an
apparent ‘effect modification’ by aggressiveness of the disease at diagnosis (Garcia-Closas and
Berrington de Gonzalez, 2015). Therefore, the heterogeneity in the association between BMI
76 6. Discussion
during middle-late adulthood and the incidence of prostate cancer by subtype of the disease
might have non-causal explanations.
First, obese men have lower mean PSA values (Bañez et al., 2007), which in turns leads to a
reduction in the rate of PSA-driven biopsies. The reason why obese men have lower PSA levels
on average is still unclear. One explanation is that obese men have lower testosterone levels,
leading to less PSA production. It has also been hypothesized that this is due to increased
blood volume in obese subjects causing PSA hemodilution, since no evidence of an association
between mean PSA mass and BMI was observed in some studies (Bañez et al., 2007; Grubb
et al., 2009).
Second, a thorough digital rectal examination is more difficult in obese men and its pre-
dictive value in prostate cancer detection has been observed to be modified by obesity (Chu
et al., 2011), which could result in missed cancers.
Third, several studies have suggested that obese men have larger prostates on average
(Dahle et al., 2002; Freedland et al., 2006b), which reduces the likelihood of finding cancer
at biopsy (Freedland et al., 2006b). Furthermore, most prostate cancers detected by PSA
screening are very small and they cannot be visualized with conventional imaging, making
prostate biopsy “analogous to looking for a needle in a haystack” (Buschemeyer and Freedland,
2007). Therefore, prostatic enlargement in obese men would make biopsy detection even more
complicated, all other things being equal (Kranse et al., 1999).
All these factors combined could potentially allow prostate cancer growth to continue
undetected. This would eventually result in a higher occurrence of advanced disease in obese
men as compared with normal-weight men and, at the same time, in a lower occurrence of
localized disease.
To what extent detection bias explains the results reported in epidemiologic studies, includ-
ing ours, it is unknown. However, even in the pre-PSA era obesity was positively associated with
prostate cancer mortality (Rodriguez et al., 2001). Furthermore, obesity has been observed
to be associated with decreased odds of low-grade prostate cancer and, at the same time, in-
creased odds of high-grade prostate cancer even when all men underwent biopsy (Gong et al.,
2006). Detection bias is therefore unlikely to fully explain the association between BMI and
prostate cancer mortality, and the subtype-specific associations with prostate cancer incidence.
Lastly, in our data we observed no evidence of heterogeneity in the associations by county
of enrollment (table 5.1).27 Although this analysis is obviously sub-optimal — men enrolled in
one county may have in fact moved somewhere else during the follow-up time — it provides
no evidence in support of the hypothesis that the observed associations are due to detection
bias.
27County of enrollment reflected possible different degrees of PSA-screening uptake. See section 4.3.1.
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6.1.4 Body mass index as surrogate of obesity
The usage of BMI as a proxy for obesity — “a condition characterized by the excessive accumu-
lation and storage of fat in the body”28 — has some limitations. At the same time, thanks to
its simplicity and cost-effectiveness, BMI is likely the most commonly used measure of obesity
in large-scale epidemiologic studies (Michels et al., 1998).
The major shortcoming of this measure is probably that single individuals’ specific com-
position and body shape do not enter into BMI calculations. For example, very muscular men
with little body fat can have a high BMI, which would be wrongly interpreted as an indication
of obesity. However, these types of men arguably constitute a limited proportion of the men
enrolled in most studies, with an exception possibly being the Swedish Construction Workers
cohort (Stocks et al., 2010), which was included in the meta-analysis of Paper IV.
Although BMI may be inadequate to measure body adiposity for a single subject, it remains
a reasonably accurate measure of body adiposity in populations (Flegal et al., 2009). However,
a systematic tendency to over-report height and under-report weight, resulting in BMI being
biased downwards, has been repeatedly observed (Connor Gorber et al., 2007). Perhaps not
surprisingly, this tendency to under-report weight has been observed to be more common
among overweight and obese individual than among normal-weight individuals (Boström and
Diderichsen, 1997; Kovalchik, 2009).
The consequences of this measurement error depend on the “true” unknown underlying
association that is being examined. For example, for advanced and fatal prostate cancer risk
— assuming that the “true” association with BMI during middle-late adulthood is positive — a
systematic under-reporting of BMI in obese men would lead to attenuated associations (RRs
closer to the unity).
6.2 Survival percentiles when age at the event is the relevant
time scale
When describing survival data from observational epidemiologic studies, the standard approach
is to focus on the hazard function, while differences in survival between groups of individuals
are usually summarized by means of HRRs. The reason for the ubiquitous presence of HRRs
in the epidemiologic literature is arguably due to the wide availability of statistical tools to
directly model the hazard as a function of some covariates of interest, and not to the fact that
HRRs are inherently “better” measures of association than others (Hernán, 2010; Uno et al.,
2014).
A different approach to describe survival data consists in focusing on survival percentiles,
which thoroughly describe the distribution of survival time. Survival percentiles provide the
link between the proportion of study subjects that has experienced the event of interest and
the time by which that proportion is reached.
28http://www.merriam-webster.com/dictionary/obesity
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As survival percentiles can be obtained from survival curves, both hazard models and the
Kaplan-Meier estimator can be utilized to “indirectly” estimate them.29 As seen in section 2.2.2,
however, calculating survival curves following PH models can sometimes give a “misleading
impression” (Kalbfleisch and Prentice, 2002) and is impractical if one wants to relax the PH
assumption by employing time-dependent coefficients. Moreover, calculation of confidence
intervals for survival percentiles obtained in this way is not straightforward (Burr, 1994; Lai
and Su, 2006). The Kaplan-Meier estimator, on the other hand, is often inadequate in the
context of observational epidemiology, where modeling is generally preferred over simple
stratification.
Quantile regression for censored data, on the other hand, focuses directly on survival
percentiles posing no restrictions on the shape of the survival function and offers all those
advantages of statistical modeling that are so important in the analysis of observational data.
In Paper II, we proposed an intuitive and simple approach to extend the use of Laplace
regression to those situations in which investigators want to use age as the underlying time
scale. We showed that delayed entries, introduced by the change in the time scale, complicate
the interpretation of survival percentiles obtained from survival curves. In fact, in the presence
of delayed entries, it is no longer true that the 100p-th percentile of attained age, say a(p),
can be interpreted as the age by which 100p% of the study population has experienced the
event of interest. It may even occur, for example, that by age a(p) less than 100p% of study
participants have been enrolled in the study.
By conditioning the quantile regression model on age at entry (baseline age), the 100p-th
survival percentile of age at the event can now be interpreted as the age by which 100p% of
the study participants have experienced the event, given a fixed baseline age. Moreover, the
model coefficients express the difference in the 100p-th percentile of age at the event between
exposed and unexposed individuals, always conditional on baseline age. We think that this
extension can be particularly useful for the analysis of observational studies, where attained
age is often a more meaningful and natural time scale than time elapsed since some arbitrary
baseline event.
As previously written, survival percentiles thoroughly describe the distribution of survival
time, and likewise PDs give a full picture of the differences in the distribution of age-at-event
between exposed and unexposed individuals. This can be, however, a double-edged sword. In
fact, unless one is interested in a pre-specified PD (as it could be the case for clinical trials),
the richer picture provided by PDs also requires more information to be reported (in terms
of figures, words and/or numbers). Focusing on one single arbitrary chosen PD can give a
“misleading impression” of the association just like reporting one single HRR when the PH does
not seem to hold. In the illustrative example in Paper II, we reported differences in the 25th,
50th, and 75th percentiles of age at death according to smoking status for this reason.
29The word “indirectly” is used to highlight the fact that, both in the case of hazard models and Kaplan-Meier
estimator, what is actually being estimated are survival probabilities given study time.
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Laplace regression
Among the different available methods for quantile regression for censored data, in this thesis
and in Paper II, we employed Laplace regression, whose principal characteristic is probably
the Laplacian distributional assumption of the error term. This assumption is shared by other
methods for quantile regression (Liu and Bottai, 2009; Farcomeni, 2010; Lee and Neocleous,
2010; Yuan and Yin, 2010). Other proposed techniques do not make distributional assumptions
on the error term but are subject to other assumptions, such as global linearity (Portnoy, 2003;
Peng and Huang, 2008), not required by Laplace regression. The method by Wang and Wang
(2009) overcomes the global-linearity assumption but its computational algorithm requires
subjectively setting a smoothing function, which may ultimately have an impact on inference.
Laplace regression has been observed to be robust to violations of the Laplacian distribu-
tional assumption. In simulation studies where the error term was generated from a number of
different distributions — including normal, lognormal, Student’s t, and exponential distribu-
tion — the performances of the Laplace estimator in terms of bias and coverage were observed
to be remarkably good, even at high quantiles and with large rates of censoring (Bottai and
Zhang, 2010, 2011; Bottai and Orsini, 2013; Bottai et al., 2015).
6.3 Risk and rate advancement periods
RAP reflects the exposure impact in the timing of the disease occurrence. For rates, RAP
quantifies how much sooner e1-exposed individuals reach the same IR of a certain disease
as e0-exposed individuals, under the assumptions of a monotonically increasing age-disease
association and disease-free survival to baseline age.
The fact that RAP is a time-based measure of exposure impact makes it very appealing in
risk communication. For example, in a recent paper published in the British Medical Journal,
Mons et al. (2015) wrote that “risk communication is [...] crucial [...] and risk advancement
periods could be easier to grasp for the general public than other epidemiologic risk measures
such as relative risks of years of life lost”. Whether this is actually true or not remains to
be seen, as no empirical evidence on the usefulness of RAP in risk communication with lay
audiences has been collected yet.
What we have observed, however, is the fact that correct interpretation of RAP has eluded
many of the studies that have employed this measure so far. In particular, we have identified
three major conceptual problems. First, equating RAP with the difference in mean survival time;
second, interpreting RAP as the time by which the survival curve for the e1-exposed individuals
is shifted with respect to the survival curve for the e0-exposed individuals; third, equating
the RAP concept to that of RRs. Furthermore, we have highlighted a too often neglected
statistical problem, which is the high sensitivity of RAP estimates to the form of the age-disease
association. All these problems can be quite serious in realistic examples.
The reason why RAP has been repeatedly misinterpreted in the literature is most likely
multi-factorial, but a possible explanation is that RAP is a measure involving three variables
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(exposure, baseline age, and binary outcome) instead of two as traditional measures of asso-
ciation. As RAP evaluates the impact of the exposure on the relation of age to the outcome,
it is more similar to an interaction measure than to a measure of association, although it is
not equivalent to a product term in the model. This supplementary complexity might partially
explain why RAP has been repeatedly misinterpreted.
RAP in prostate cancer epidemiology
A crucial assumption for sensible use of RAP is that the rate of the outcome strictly increases
with age, given exposure and confounders. If this assumption is not met, one should avoid use
of RAP. As seen in the COSM (figure 4.1) and in other populations (Ferlay et al., 2015), the
incidence of prostate cancer increases until around 70–74 years of age and declines thereafter.
This is likely due to less use of PSA-testing in men over 80 years of age (Williams et al., 2011)
and, at the same time, to a constant increase over time in PSA-testing among younger men
(Salinas et al., 2014). Although the reasons behind the non-monotonicity of the age-incidence
curve are unlikely to be biological, this limits the application of RAP in this context. A possible
solution is to restrict RAP analysis to men younger than 70–74 years of age to ensure that the
assumption of a monotonic increase in disease rate over age holds.
In contrast, the monotonicity assumption seems to hold for prostate cancer mortality (Fer-
lay et al., 2015). In the example reported in section 5.3.3 using data from the COSM, obese
men were observed to experience the same prostate cancer MR over the follow-up period
1998–2012 as that of normal-weight men who were 18 months older at baseline. Despite the
lack of evidence of a non-linear association between age and log–mortality rate of prostate
cancer, RAP estimates were somewhat sensitive to the functional form with which baseline age
entered into the model.
Lastly, interpretation of RAP as the time period by which attainment of a particular rate
level can be postponed by eliminating the exposure requires the (conditional) independence
of the study disease from competing events. As Brenner et al. (1993) wrote “this limitation is
negligible if the RAP is derived for young and middle-aged individuals and if the RAP is not
too long”. In the case of prostate cancer mortality, on the other hand, since the vast majority of
men dying of the disease are elderly, interpretation of RAP estimates becomes more theoretical.
6.4 Goodness of fit assessment in dose–responsemeta-analysis
6.4.1 Why goodness of fit assessment is important
Statistical modeling in the context of dose–response meta-analysis can be thought of as ‘de-
scriptive modeling’ (Rosenthal and Rubin, 1985; Shmueli, 2010). Citing the words by Shmueli
(2010) “this type of modeling is aimed at summarizing or representing the data structure in a
compact manner”.
In order to give a fair representation of the data structure — that is, of the information
regarding a certain dose-risk relation — one should make sure that the posited dose–response
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meta-analysis models actually provide an adequate description of the data at hand. Therefore,
we argue that the natural ‘third stage’ of a dose–response meta-analysis should be the evalua-
tion of its goodness of fit, which can be done in practice by measuring the degree of agreement
between fitted and observed data.
A poor fit can raise doubts about the ability of a certain model to summarize the available
data or as Greenland (1994) put it “if one views statistical estimates as data summaries, then
one can view significant lack of fit as a warning that the fitted model structure and model-based
estimates are poor data summaries”.
Despite its importance, however, the issue of how to evaluate goodness of fit of dose–
response meta-analysis models has, to the best of our knowledge, never been specifically
addressed. As a consequence, assessment of the goodness of fit is rarely, if ever, carried out in
practice. As Sutton and Higgins (2008) pointed out “little formal assessment of the goodness-
of-fit of meta-analysis models to the data is carried out. This may be partly because many
non-statisticians conduct meta-analysis, and to such applied researchers meta-analysis may be
seen as a necessary data-processing procedure rather than a model-fitting exercise”.
The aforementioned degree of agreement has been sometimes evaluated by simply over-
laying the study-specific RRs to the pooled dose–response curve (see, for example, WCRF and
AICR, 2014; Liao et al., 2015). However, although praiseworthy, this approach can be highly
misleading as the correlation among the reported logRRs means that even a well-fitting dose–
response curve might not pass through the data points. This was clearly illustrated, in the
simple case of trend estimation for one single study, in figure 5.11.
Furthermore, study-specific dose–response relations are sometimes illustrated by plotting
the reported RRs at their assigned doses and connecting them with straight lines (segments)
(WCRF and AICR, 2014). This can be misleading for the very same reasons given above. In
fact, visually inferring the dose–response relation from this kind of plot may lead to wrong
conclusions, given the that the correlation between RRs is not taken into account.
A digression on goodness of fit
The statistical modeling carried out for the description of COSM data and for the comparison
with Swedish national data (section 4.3) can also be viewed as descriptive modeling and the
same considerations about goodness of fit apply. In fact, we overlaid to the model predictions
the observed (summarized) data, so that the goodness of fit of the models could be, at least
qualitatively, evaluated.
Statistical modeling in Paper I, on the other hand, was aimed at ‘explaining’ — that is,
testing hypotheses about theoretical constructs (Shmueli, 2010). In ‘explanatory modeling’
one is not usually interested in assessing the overall absolute goodness of fit of a model, as
“the fit of the model must be evaluated only against the specific part of the variation [of the
outcome] which is relevant to the subset of effects of interest. An overall test of the model fit is
too general for this purpose and does not answer the right question” (Hagquist and Stenbeck,
1998).
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6.4.2 Deviance, coe cient of determination, and visual assessment
To highlight the need of assessing the goodness of fit in dose–response meta-analysis, we
presented and discussed in Paper V three goodness of fit tools (deviance, coefficient of determi-
nation, and decorrelated-residuals–versus–exposure plot). These tools can be useful for testing,
quantifying, and visually displaying the fit of dose–response meta-analysis models while taking
into account the correlation structure of the study-specific logRRs.
The examples given in Paper V and in section 5.5.2 showed how these tools can give
important indications regarding the fit of the candidate models. In particular, these tools
can help identify dose–response patterns, investigate sources of heterogeneity, and eventually
assess wether the pooled dose–response association adequately summarizes the published
results. Their use can strengthen the conclusion drawn from a dose–response meta-analysis
or, conversely, raise doubts about its ability to describe in an adequate manner the available
evidence. However, one should also be aware that these tools come with some limitations.
Limitations and caveats
First, while a small p-value from the test for model specification (deviance) is an indication
that the considered model fails at explaining the observed variation in the reported logRRs,
a large p-value shall not lead to the conclusion that the model adequately explains all the
observed variability. Moreover, although a small p-value is an indication that the the tested
model is unsatisfactory and needs to be modified (or completely replaced), it provides no
indication as to how to proceed. Lastly, a major drawback of all global tests of fit is their low
power to detect problems in the model (Hosmer et al., 1997).
Second, when the dose–response meta-analysis models are specified in a data-dependent
fashion (also known as data dredging), p-values from the global goodness of fit cannot be
formally regarded as valid.
Third, although a R2 = 1 does correspond to a perfect fit, interpreting a low coefficient of
determination is more complicated. In fact, R2 can be close to 0 because of different reasons:
the model fits poorly the data, the exposure and the logRRs are not associated, or simply —
even under the “correct” model — the GRSS is close to the GTSS.
Fourth, the interpretation of the decorrelated-residuals–versus–exposure plot is based on
the visual recognition of patterns in the distribution of the decorrelated residuals by levels of
the exposure, which is a subjective experience (Greenland, 1994). In the extreme situation of
sparse data, the meta-analyst can “recognize” almost any pattern in the plot.
In conclusion, a good fit alone does not imply that the “correct” model has been selected.
In extreme cases, especially when the number of data points is small, very different pooled
dose–response curves may appear to be equally satisfactory from a goodness-of-fit point of
view. This is not surprising, as it simply reflects the fact that the total amount of available
information is limited. In such cases, subject matter knowledge — that is, prior information —
will play a crucial role in selecting the final model. At the same time, goodness of fit assessment
can help to weed out those models that fail at adequately summarizing the available evidence.
Chapter 7
Conclusions
The results presented in this thesis contribute to the body of scientific evidence regarding the
association between BMI during early and middle-late adulthood and prostate cancer incidence
and mortality. Furthermore, this thesis contributes to the advancement of the epidemiologic
field by extending the use of quantile regression for censored data to those situations where
attained age is the time scale of interest, by clarifying the appropriate use and interpretation
of RAP, and by proposing useful and relevant methods to assess the goodness of fit of dose–
response models in research synthesis.
More specifically we conclude the following:
• In a large population-based cohort of Swedish men, BMI measured during middle-late
adulthood was inversely associated with the incidence of localized prostate cancer. At
the same time, BMI was directly associated with the incidence of advanced prostate
cancer and with prostate cancer mortality. BMI during early adulthood was only weakly
inversely associated with the incidence of advanced prostate cancer and with prostate
cancer mortality (Paper I).
• Similar results regarding the dual dose–response association between BMI during middle-
late adulthood and the incidence of localized and advanced prostate cancer were ob-
served by summarizing the published epidemiologic evidence. This supports the hypothe-
sis of etiological heterogeneity of prostate cancer in relation to obesity during middle-late
adulthood (Paper IV).
• The use of quantile regression for censored data can be extended to those situations
where the time scale of interest is attained age at the event instead of follow-up time. In
particular, in the presence of delayed entries, Laplace regression can be used to model
percentiles of age at the event by conditioning on baseline age (Paper II).
• The misconceptions appeared in the literature radically changed the meaning of RAP.
Moreover, we showed how this measure is extremely sensitive to the form of the age-
disease dependence in the rate or risk model. As a result, RAP can make more harm than
good if misinterpreted or estimated from misspecified models (Paper III).
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• Goodness of fit of dose–response meta-analysis models should be routinely assessed. The
tools illustrated in this thesis prove useful to test, quantify, and visually display the fit of
dose–response meta-analysis models, while taking into account the correlation structure
of the study-specific logRRs (Paper V).
Chapter 8
Future research
Based on the conclusions presented in this thesis, future research includes:
• Further investigating the role on prostate cancer incidence and mortality of obesity mea-
sured at different time points in life. Cohort studies of children, adolescents, or young
adults initiated decades ago could for example provide invaluable data to elucidate these
associations. Furthermore, linkage of cross-sectional or cohort data collected decades ago
with cancer registries could be another viable short-term option. Records of children’s
weight collected at school or military enlistment registries (military service was manda-
tory in Sweden between 1901 and 2010) could provide unique data on anthropometric
measurements.
• More in general, body fatness and changes in body weight over the life course in relation
to prostate cancer risk deserve additional investigation. This requires well-designed
prospective studies of prostate cancer–free men followed to diagnosis and to death.
Availability of repeated measurements is essential to be able to answer this question.
Moreover, differences between weight gain/loss around the time of diagnosis and long-
term weight gain/loss should be considered when focusing on prostate cancer mortality.
Lastly, one should be able to distinguish between intentional and unintentional weight
loss. Data from the COSM, thanks to the self-reported weight measurements at two time
points (1997 and 2008), could help answering some of these research questions.
• Evaluating the role played by detection bias and other alternative explanations to bio-
logical mechanisms in the association between obesity and incidence of localized and
advanced prostate cancer.
• Extending the use of survival percentiles to measures that assess the public health impact
of an exposure. For example, one could think of a percentile-based measure analogous
to the excess fraction (Greenland and Rothman, 2008), where a given PD is recalculated
as a fraction of the survival percentile among the exposed.
• Regression methods for measures of disease occurrence based on survival percentiles,
such as the geometric rate regression model (Bottai, 2015), merit further attention both
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from an applied and methodological point of view.
• Extending and applying additive models (Buja et al., 1989) to dose–response meta-
analysis. This would provide a flexible tool to investigate the shape of the dose-risk
relation. Formulae for fitting additive models by penalized least squares need to be
modified to take into account the correlation structure of the error term and the lack of
the intercept. Additive models can be used together with the one-stage meta-analysis
approach (see Paper V).
• Developing a point-wise average approach for dose–response meta-analysis, extending
the work carried out by Sauerbrei and Royston (2011) on meta-analysis of individual
patient data. One of the possible advantages that this approach would give is that the
exposure transformation is not constrained to be the same across all the individual
studies, as it is the case in the two-stage approach presented in this thesis.
• As a next step following the goodness of fit tools introduced in Paper V, it would be
valuable to develop outlier and influence diagnostics for dose–response meta-analysis.
These diagnostic tools would prove useful in sensitivity analyses to assess robustness
and stability of dose–response meta-analysis models.
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Figure A.2: SMRs of prostate cancer by attained age. The solid line is the model-based predicted SMR,
while dashed lines are 95% confidence intervals. The hollow circles represent the observed SMRs by
5-year categories of attained age together with 95% confidence intervals. The confidence interval for
SMR2,· was not displayed since extremely wide, as it was based on 1 death only. Moreover, given that
no deaths were observed in the category 45–49 years of attained age, the graph starts at age 50 years
(see Table B.2). The vertical axis is on the natural log scale.
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Figure A.3: Multivariable-adjusted associations of BMI at age 30 years (kg⇥m 2) with IR of localized
and advanced prostate cancer, and with MR of fatal prostate cancer in the updated analysis of Paper I.
BMI was modeled using RCS with 4 knots (blue line) and linearly (red line). The referent value was
set at 22 kg⇥m 2. Vertical lines above the curves represent cases of prostate cancer. The vertical axes
are on the natural log scale.
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Figure A.4: Study-specific dose–response associations between BMI and incidence of advanced prostate
cancer in the updated meta-analysis including 18 prospective studies. BMI was modeled using RCS
with 3 knots positioned at the 10th, 50th, and 90th percentiles of the overall BMI distribution (blue
line) and in a linear fashion (red line). Dashed black lines represent the 95% CI for the RCS models.
The vertical axes are on the natural log scale. Figure continued on next page.
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Figure A.5: RRs of advanced prostate cancer for every 5-unit increment in BMI for the updated dose–
response meta-analysis on 18 prospective studies. The size of each square is proportional to the weight
of the study (inverse of within- plus between-study variances)
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Table B.1: Observed number of incident prostate cancer cases in the COSM by calendar year and
attained age (top entry), and expected number of cases obtained by applying Swedish national rates to
the COSM calendar-year and age structure (bottom entry).
Calendar Attained age (years)
year 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ Total
1998 1 1 8 26 36 48 49 4 173
0 3 9 19 39 46 48 4 168
1999 0 5 16 28 39 61 64 10 223
0 4 12 24 40 51 54 12 197
2000 0 6 16 33 40 43 65 23 226
0 4 14 25 41 52 54 21 212
2001 0 5 16 32 59 47 61 36 256
0 5 16 28 41 51 50 28 220
2002 0 4 23 27 46 51 69 38 0 258
0 5 17 32 40 52 50 35 0 232
2003 6 26 53 63 79 72 59 5 363
5 21 38 48 58 56 39 2 269
2004 7 15 50 57 74 72 47 7 329
5 25 47 56 63 55 37 5 293
2005 4 28 47 77 60 76 51 13 356
3 23 47 55 56 54 40 9 288
2006 2 22 34 58 49 49 40 21 275
2 23 47 51 50 48 36 13 269
2007 0 21 57 57 58 36 51 29 309
1 20 43 54 46 45 34 13 256
2008 19 52 75 39 49 35 34 303
16 43 51 44 43 32 16 246
2009 15 70 72 49 59 47 31 343
14 50 65 55 48 33 18 284
2010 9 52 57 59 54 30 20 281
9 43 61 52 44 32 16 257
2011 7 41 63 61 39 45 19 275
5 41 62 51 39 31 18 247
2012 5 28 63 48 46 32 21 243
2 34 58 49 34 27 18 221
Total 1 40 246 630 862 826 860 548 200 4,213
1 37 227 561 761 776 722 441 128 3,656
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Table B.2: Observed number of prostate cancer deaths in the COSM by calendar year and attained age
(top entry), and expected number of deaths obtained by applying Swedish national rates to the COSM
calendar-year and age structure (bottom entry).
Calendar Attained age (years)
year 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ Total
1998 0 0 0 1 0 1 0 0 2
0 0 1 2 6 12 18 2 43
1999 0 0 0 0 1 1 3 0 5
0 0 1 2 6 12 19 7 47
2000 0 0 1 2 1 2 8 3 17
0 0 1 3 6 12 20 12 53
2001 0 0 0 1 4 3 14 4 26
0 0 1 3 6 11 19 16 56
2002 0 0 1 7 1 5 8 11 0 33
0 0 1 2 4 11 17 20 0 56
2003 1 1 5 1 7 15 20 2 52
0 1 3 5 13 21 23 3 69
2004 0 1 3 4 6 14 12 7 47
0 1 2 7 11 18 23 8 70
2005 0 1 2 6 9 10 16 3 47
0 1 3 6 11 18 23 11 73
2006 0 1 2 5 4 16 20 7 55
0 1 3 5 9 17 24 17 77
2007 0 1 1 6 6 11 23 16 64
0 1 3 5 9 18 23 21 79
2008 0 4 5 5 12 13 17 56
1 3 5 8 16 24 26 82
2009 2 5 8 5 6 10 22 58
1 2 5 9 15 22 28 81
2010 0 1 1 6 14 18 30 70
0 2 5 8 15 22 30 82
2011 0 2 7 9 14 21 34 87
0 2 6 8 13 21 32 82
2012 0 0 2 8 11 21 30 72
0 2 5 8 12 22 34 84
Total 0 1 9 36 52 77 156 192 168 691
0 2 12 37 82 152 255 284 209 1,034
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